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Glyconanobiotics: Novel Carbohydrated Nanoparticle Polymers 
 
Thotaha Wijayahewage Sampath Chrysantha Abeylath 
 
ABSTRACT 
 
 
 Carbohydrates on the cell surface conjugates to proteins and lipids and participates in biological 
processes as glycoconjugates. Carbohydrate functionalized nanoparticles (glyconanoparticles) constitute a 
good bio-mimetic model of carbohydrate presentation at the cell surface and are currently centered on 
many glycobiological and biomedical applications. The most of the applications have been reported using 
gold glyconanoparticles. A brief review of gold glyconanoparticles and some of their applications will be 
discussed in Chapter I. Although metallic, semiconductor and magnetic glyconanoparticles have been 
reported, no polyacrylate glyconanoparticles have yet to be described. 
 
 Chapter II describes the first preparation of carbohydrate functionalized polymer nanoparticles 
by microemulsion polymerization and their characterization using scanning electron microscopy, dynamic 
light scattering and 1H NMR spectroscopy. This methodology can generate a large number of furanose and 
pyranose  nanoparticle derivatives with an average particle size of around 40 nm with the protected 
carbohydrate hydroxyl functionality as acetyl or dimethylacetal groups. Formation of larger 
glyconanoparticles of around 80 nm with 3-O-acryloyl-D-glucose and 5-O-acryloyl-1-methoxy-β-D-
ribofuranose reveals the influence of free hydroxyl groups in the monomer on the particle size during 
polymerization, a feature which is also apparently dependent on the amount of carbohydrate in the matrix.  
 
 Preparation of glyconanoparticle antibiotics, or glyconanobiotics, by microemulsion of 
antibiotic-conjugated carbohydrate monomers demonstrates for the first time the use of glyconanoparticles 
as drug delivery vehicles in Chapter III. The conjugation of an acrylated hydrophobic carbohydrate moiety 
to the lipophilic antibiotic makes it even more lipophilic and suitable as a co-monomer in microemulsion 
polymerization with styrene/butyl acrylate. Novel carbohydrate-based acrylated acyl chlorides synthesized 
from glucose afford antibiotic monomers with enhanced lipophilicity in a one step procedure. These drug 
monomers and the corresponding glyconanobiotics prepared by conjugating antibiotics such as N-thiolated-
β-lactam, ciprofloxacin, and penicillin shows biological activity against S. aureus, MRSA and B. anthracis 
microbes.  
 
 Glyconanoparticles prepared by microemulsion polymerization of 3-O-acryloyl-D-glucose and 
styrene/butyl acrylate may be potentially used as recognition units in carbohydrate ligand mediated targeted 
drug delivery. The binding capability of the surface-exposed carbohydrates on the nanoparticle can be 
detected by fluorescence spectroscopy utilizing pyranine and 4,4’-N,N-bis(benzyl-2-boronic acid)-
bipyridinium dibromide as described in Chapter IV.  
 
 
 
 
 
 
 
 
xii 
CHAPTER I 
 
GLYCONANOPARTICLES IN GLYCOSCIENCE AND BIOMEDICINE 
 
 
1.1 Introduction 
 
 Carbohydrates are, together with nucleic acids and proteins, important molecules of life. Much is 
already known about the structure, interactions and function of nucleic acids and proteins. However, the 
role of carbohydrates in the cell is less clear. The surface of mammalian cells is covered by a dense coating 
of carbohydrates named glycocalyx.1 In the glycocalyx, carbohydrates appear mainly conjugated to proteins 
and lipids (glycoproteins and  glycolipids) and it is as glycoconjugates that they develop their biological 
function.  Now, it is known that these complex oligosaccharides are involved in the control of many normal 
and pathological processes. 2,3 Hakomori in 1989 proposed that the first phase of cell adhesion initiates 
through a carbohydrate-carbohydrate interaction between multivalent glycosphingolipid-domains. This 
initial step is followed by protein-protein interactions between adhesion receptors and protein-carbohydrate 
interactions between lectins and glycoconjugates. Embryogenesis, metastasis and other cellular 
proliferation processes are mediated by carbohydrate-carbohydrate interactions, according to Hakomori. 4-9 
 
Figure 1.1: Structures of GM3, Gg3 and KDNGM3 glycosphingolipids  
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Several glycosphingolipids involved in carbohydrate-carbohydrate interactions have already been identified. 
For example, the interaction between the glycosphingolipids GM3 and Gg3 has been proposed to be involved in 
metastasis of melanoma cells in mouse. 6-8 It has been demonstrated recently that the interaction between 
KDNGM3 and Gg3 is involved in the binding of sperm to egg membrane in rainbow trout fertilization 9(Figure 
1.1).  
 
 Since nanoparticles and biomolecules are of similar dimensions,  nanoparticles can imitate 
biomolecular presentation in cellular systems, probing the mechanisms of biological processes, as well as 
developing chemical means for handling and manipulating biological components.10 Although several groups 
have prepared  nanoparticles functionalized with proteins and DNA11 during the last 10 years  for this purpose, 
carbohydrates had not been used to functionalize nanoparticles until the first synthesis of carbohydrate 
functionalized gold nanoparticles (glyconanoparticles) were reported in 2001.12 The glyconanoparticles can 
mimic carbohydrate presentation to glycoproteins  or  glycosphingolipids patches, by providing a glycocalyx-
like surface, presenting carbohydrates in a globular and polyvalent configuration on their surface. Also 
glyconanoparticles have unusual physical properties due to the quantum size effect that can be used for the 
detection and evaluation of the interactions where carbohydrates are involved. 13,14 
 
 In spite of the short history of these new glyconanomaterials, some applications have already been 
reported in the field of chemical glycobiology mainly focusing on the study and evaluation of carbohydrate 
interactions. Furthermore, reports have appeared on glyconanoparticles in applications to biomedicine.  
 
 Gold and silver glyconanoparticles, semiconductor glycol-quantum dots and magnetic 
glyconanoparticles are the three different types of nanoparticles functionalized with carbohydrates so far and the 
most of the applications have been reported using gold glyconanoparticles. This chapter discusses the 
preparation of gold glyconanoparticles and some of their applications in glycoscience and biomedicine.  
 
 
1.2 Gold glyconanoparticles 
 
 Gold nanoparticles are the most stable metal nanoparticles. The first synthesis of gold 
glyconanoparticles was carried out by adding a methanolic solution of thiol-derivatized carbohydrate 
compounds called neoglycoconjugates  to an aqueous solution of tetrachloroauric acid (HAuCl4) and 
subsequent reduction with NaBH4.12 Three neoglycoconjugates of two biologically significant oligosaccharides, 
the disaccharide lactose (Galβ(1-4)Glcβ1-OR) and the trisaccharide  Lex (Galβ(1-4)[Fucα(1-3)]GlcNAcβ1-OR),  
were used for this purpose (Scheme 1.1). 
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Scheme 1.1: Preparation of gold glyconanoparticles 
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This approach opened the way to tailoring glyconanoparticles with a variety of carbohydrate ligands. Following 
this method, the synthesis of different glyconanoparticles functionalized with the monosaccharide glucose, 
disaccharide maltose (Glcα1-4Glcβ1)15 and tetrasaccharide Ley ([Fucα1-2]Galβ1-4[Fucα1-2]GlcNAcβ1) 16 have 
been reported (Figure 1.2). 
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Figure 1.2: Structures of thiol-derivatized neoglycoconjugates; monosaccharide (glucose), disaccharide    
      (maltose) and tetrasaccharide (Ley) 
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Different linkers of hydrophobic (alkyl) and hydrophilic (polyethylene glycol derivatives) have been used to 
bind the carbohydrate to the gold core. 15 The glyconanoparticles prepared in this way are water soluble, stable 
in solution for years, non-cytotoxic and exceptionally small (less than 2 nm). 13,17  
 
 
1.3  Glyconanoparticles to study protein-protein interactions 
 
 Gold glyconanoparticles have been used extensively to study protein-carbohydrate interactions. 18 Also 
more recently, Chen et al. have applied the visible color change for the detection of protein-protein interactions 
19 using glyconanoparticles. Thyroglobulin, a binding protein for glycoprotein- Concanavalin A, was added to 
mannopyranoside-encapsulated glyconanoparticles complexed to Concanavalin A. The color change from 
purple to pinkish red, due to the dispersion of glyconanoparticles, allowed the qualitatively and quantitatively 
evaluation of the thyroglobulin-Concanavalin A interaction (Figure 1.3). 
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Figure 1.3: A schematic illustration for the colorimetric detection of protein-protein interactions. (a) gold 
glyconanoparticles (b) agglomeration of the glycoparticles via glyconanoparticle-ConA interactions (purple)  
(c) dissipation of the glyconanoparticles by formation of thyroglobulin-ConA interactions (pinkish red). 
 
 
: Concanavalin A :Thyroglobulin: Glyconanoparticles
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1.4 Glyconanoparticles as biolabels 
 
 Glyconanoparticles can be used as efficient labeling probes in a biological system. Lin et al. have 
demonstrated the selective binding of mannose-encapsulated gold nanoparticles to adhesin FimH  of  type 1 pili 
in Escherichia coli  by transmission electron microscopy (TEM). 20 Adherence is often an essential step in 
bacterial pathogenesis. To effectively adhere to host surfaces, many bacteria produce multiple adherence factors 
called adhesins. Type 1 pili are filamentous protein structures that extend from the surface of many gram-
negative organisms and are composed of FimA, FimF, FimG, and FimH proteins. 21 FimA accounts for more 
than 98% of the protein and FimH is uniquely responsible for the binding to D-mannose. 22 They have used two 
E. coli strains ORN178 and ORN208 in experiments to confirm the binding of mannose nanoparticles, 
synthesized from thiomannosyl dimmer (Scheme 1.2), to FimH. The ORN178 strain expresses wild-type type-1 
pili, whereas the ORN208 strain is deficient of the FimH and expresses abnormal type 1 pili that fail to mediate 
D-mannose specific binding. After incubating the two bacterial strains separately with mannose gold 
nanoparticles and examining by TEM, selective binding of the glconanoparticles to the ORN178 has been 
observed (Figure 1.4). The selective binding of these glyconanoparticles to bacterial type I pili presented a 
novel method of labeling specific receptors for carbohydrates on the cell surface using carbohydrate-conjugated 
nanoparticles.   
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Scheme 1.2:  Synthesis of mannose-conjugated gold nanoparticles from thiomannosyl dimer 
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Figure 1.4: Mannose-conjugated gold nanoparticles binding to the specific receptor of type 1 pili 
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1.5  Glyconanoparticles in biomedicine 
 
 Since glyconanoparticles represent good biomimetic models of carbohydrate-mediated biological 
processes, they have been applied in a variety of biomedical applications. Lactose gold glyconanoparticles have 
been shown as potential tools in anti-adhesive therapy.23 Metastasis is the origin of the poor prognosis of most 
cancers. One of the critical steps in metastasis is the adhesion of tumor cells to the vascular endothelium. After 
adhesion, tumor cells migrate and create new tumor foci. 24 Interactions between tumour-associated antigens and 
epithelial cell selectins promote tumor cell metastasis. 25 In addition to this mechanism, carbohydrate-
carbohydrate interactions between glycosphingolipids expressed on the tumor and endothelial cell surfaces also 
seem to be involved in the critical adhesion step. 26 A carbohydrate-carbohydrate interaction between GM3 
expressed in a murine melanoma cell line (B16) and Gg3 of endothelium cells has been proposed to be involved 
in the first adhesion step of tumor cells to endothelium before transmigration. 27,28 Therefore, inhibition of this 
step by glyconanoparticles that present carbohydrate antigens expressed either in the tumor or the endothelium 
cells might provide effective anti-adhesion therapy as shown in Figure 1.5.  
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Figure 1.5: Possible mechanism of lactose glyconanoparticles in anti-adhesive therapy23  
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Based on the involvement of the antigen lactosylceramide in cell adhesion, lactose-conjugated 
glyconanoparticles have been tested as a potential inhibitor of the binding of melanoma cells to endothelium.23 
According to the experiment designed for the evaluation of the anti-metastasis potential of the 
glyconanoparticles, mice were injected with melanoma cells pre-incubated with lactose-bound gold 
nanoparticles. After three weeks, the animals were sacrificed and both lungs were evaluated under the 
microscope for analysis of tumor foci.  70% of the tumor growth was found to be inhibited, as compared with 
the group inoculated only with melanoma cells. 
 
 
1.6 Conclusions 
 
 In this chapter, the preparation of water-soluble and stable gold glyconanoparticles and some of their 
applications were discussed. These nanomaterials are good biomimetic models of carbohydrate presentation at 
the cell surface. These multivalent systems, having carbohydrate-mediated interactions, have opened up 
applications in the field of glycobiology. Also the simple and flexible preparation of these glyconanoparticles 
and their interesting physical, chemical and biological properties allow them to find utility in biomedicine. The 
use of carbohydrate ligands to target protein receptors, a process termed glycotargeting, is a promising approach 
in targeted drug delivery. Drug-conjugated glyconanoparticles provide a variety of new avenues and 
opportunities in ligand-mediated targeted drug delivery.  In the next chapter, the preparation of polyacrylate 
glyconanoparticles by emulsion polymerization will be discussed for the biomedical uses of antibiotic-laden 
glyconanoparticles.  
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CHAPTER II 
 
GLYCOSYLATED POLYACRYLATE NANOPARTICLES BY EMULSION POLYMERIZATION 
 
 
2.1 Introduction 
 
 Synthetic carbohydrate polymers, with biocompatible and biodegradable properties, are increasingly 
used for investigating glycopolymer-protein interactions.29 Also these glycopolymers have been widely 
investigated for pharmaceutical and medical applications in the treatment of infectious diseases.30  Several types 
of glycopolymers (as shown in Fig. 2.1) have been synthesized by free radical polymerization of vinyl 
monomers with pendent saccharide residues 31 and carbohydrate-carrying acrylates. 32, 33 Glyconanoparticles 
have been used in a variety of applications as mentioned in the previous chapter and all of these nanomaterials 
have been prepared by conjugating carbohydrates to metallic or semiconducting nanostructures. Although  the 
preparation of poly(γ-benzyl L-glutamate) (PBLG) or poly(lactic acid) (PLA) nanoparticles using a 
carbohydrate-carrying polystyrene (PS) amphiphilic polymer, which serves as both an emulsifier and a surface 
coating, has been reported as a liver-specific targeting material to deliver drugs34,35, no polyacrylate 
glyconanoparticles have yet to be described. Recently, the Turos group reported the formation of antibacterially 
 
Figure 2.1: Chemical structures of glycopolymers prepared with protected (a) glucose and (b) galactose.  
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-active polyacrylate nanoparticles by emulsion polymerization using N-thiolated β-lactam acrylates as co-
monomers in a soluble mixture of butyl acrylate-styrene.36 These antibiotic-attached polyacrylate nanoparticles 
showed activity against Staphylococcus aureus ( S. aureus) and methicillin-resistant Staphylococcus aureus  
(MRSA). This development sparked the idea of carbohydrate-bearing polyacrylate nanoparticles (polymer 
glyconanoparticles) by microemulsion polymerization serving as new drug delivery vehicles. The carbohydrate 
itself can thereby serve as a linker unit and as a recognition unit in carbohydrate-ligand mediated targeted drug 
delivery (glycotargting) systems. This chapter will present the preparation and characterization of the polymer 
glyconanoparticles and investigation of the effect of chemical structure of the carbohydrate monomer on the 
glyconanoparticle preparation. 
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2.2 Polymerization in microemulsion 
 
The first description of a microemulsion was published by Hoar and Schulman in 1943.37 Sixteen years 
later, Schulman et al. also postulated a mechanism for its formation and introduced the notation “ 
microemulsion ”. 38 Polymerization in a microemulsion is a polymerization technique which allows the 
synthesis of ultrafine latex particles in the nanometer range and with narrow size distribution. They are 
isotropic, transparent or translucent, and thermodynamically stable.  
 
 A typical microemulsion polymerization formation comprises monomer, water, surfactant and a water 
soluble initiator. Surfactant (or the emulsifier) refers to a surface active agent and contains both hydrophobic 
and hydrophilic components. These molecules are semi-soluble in both organic and aqueous solvents 
accumulating at the interface and changing the surface tension. Based on their dissociation in water, surfactants 
are classified as anionic, nonionic, cationic, zwitterionic and nonionic surfactants. The initiator reacts with a 
monomer to form an intermediate compound capable of linking successively with a large number of other 
monomers into a polymeric compound. In a free radical polymerization, the choice of polymerization initiator 
depends mainly on two factors: its solubility and its decomposition temperature. If the polymerization is 
performed in water, the initiator should be water soluble and the decomposition temperature of the initiator 
must be at or below the boiling point of water. 
 
The reaction system is characterized by the emulsified monomer droplets dispersed in the continuous 
aqueous phase with the aid of an oil-in-water surfactant at the very beginning of polymerization. Monomer 
swollen micelles exist in the reaction system provided that the concentration of surfactant in the aqueous phase 
is above its critical micelle concentration (CMC). Only a small fraction of the relatively hydrophobic monomer 
is present in the micelles or dissolved in the aqueous phase. Most of the monomer molecules dwell in the giant 
monomer reservoirs (monomer droplets). The polymerization is initiated by the addition of initiator. According 
to the micelle nucleation model, waterborne free radicals first polymerize with monomer molecules dissolved in 
the continuous aqueous phase. This would result in the increased hydrophobicity of oligomeric radicals. When 
the critical chain length is achieved, these oligomeric radicals become so hydrophobic that they show a strong 
tendency to enter the monomer-swollen micelles and then continue to propagate by reacting with those 
monomer molecules therein. As a consequence, monomer-swollen micelles are successfully transformed into 
particle nuclei. These embryo particles continue to grow by acquiring the reactant species from monomer 
droplets and monomer-swollen micelles. The particle growth stage ends when monomer droplets disappear in 
the polymerization system. In the final stage, the concentration of monomer in the reaction loci continues to 
decrease toward the end of the polymerization. 
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Figure 2.2: Schematic representation of the micelle nucleation model39 
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Acrylates, or esters of acrylic acid, are suitable to be used in emulsion polymerization. Emulsion polymerization 
of several monomers including butyl acrylate, methyl methacrylate and methyl acrylate has been reported for 
the formation of nanoparticles.40 These monomers serve as the basis of these studies.  
 
 
2.3 Synthesis of carbohydrate acrylate monomers 
 
Carbohydrate monomers required for free-radical emulsion polymerization were prepared in the form 
of acrylates or acrylamides. Acrylation can be achieved at a sugar hydroxyl or amino group after protecting the 
other OH groups in the molecule. For the preparation of polymeric glyconanoparticles, a variety of structurally 
diverse monosaccharide acrylates derived from glucose, ribose, mannose, galactose and glucosamine were 
synthesized as co-monomers (Figure 2.1). The following section describes the synthetic procedures for the 
preparation of these monomers from their relevant commercially available monosaccharides. 
 
Figure 2.3: Carbohydrate monomers  used for the formation of  glyconanoparticles: 3-acryloyl-1,2:5,6-di-O-
isopropylidene-α-D-glucofuranose (1), 1-acryloyl- 2,3:5,6-di-O-isopropylidene-α-D-mannofuranose (2), 6-
acryloyl-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose (3), N-acryloyl 1,3,4,6-tetra-O-acetyl-β-D-
glucosamine (4), and 5-O-acryloyl -2,3-isopropylidene-1-methoxy-β-D-ribofuranose (5). 
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2.3.1 O-Isopropylidene protected carbohydrate acrylates 1-4 
 
Carbohydrate acrylates derived from glucose, galactose, mannose and ribose were prepared by a two-
step procedure (as shown in Scheme 2.1) via the corresponding acetonides. The diacetonides 6 and 7  
 
Scheme 2.1: Synthesis of O-isopropylidene protected carbohydrate acrylates 
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Conditions: (a) acetone, CuSO4, H2SO4, (yields: 6,7 =82, 83% ); (b) acryloyl chloride, Et3N, CH2Cl2 (yields: 
1,2,3,4 =68, 65, 62, 65% ); (c) acetone, ZnCl2, H3PO4, P2O5, 85% ;(d) acetone, 2,2-dimethoxy propane, MeOH, 
HCl, 86%. 
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were synthesized from glucose and galactose respectively using acetone with concentrated H2SO4 as catalyst.41 
As the use of this procedure resulted in a low yield of compound 8, the acetonation of mannose was achieved 
with ZnCl2 in combination with H3PO4.42  2,2-Dimethoxypropane with acetone was used to prepare O-
isopropylidene derivative 9 from ribose.41 Acrylation of these acetonides with acryloyl chlorides and Et3N in 
CH2Cl2 afforded monomers 1, 2, 3 and 4 in high yields.  
 
 
2.3.2 O-acetal protected acrylamide from glucosamine 
 
Scheme 2.2: Synthesis of N-acryloyl 1,3,4,6-tetra-O-acetyl-β-D-glucosamine 
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Conditions: (a) aq NaOH, p-anisaldehyde,70%; (b) Py, Ac2O, 80%; (c) acetone, 5M HCl, 85%; (d) acryloyl 
chloride, Et3N, CH2Cl2, 65%. 
 
Compound 12 was obtained from commercially available D-glucosamine hydrochloride in a procedure 43 that 
used p-anisaldehyde for protection of the amine (compound 10), acetylation (compound 11) and removal of the 
p-methoxybenzylidene group with HCl in acetone (compound 12). Acrylation of this product with acryloyl 
chloride and Et3N in CH2Cl2 afforded compound 5.  
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2.4 Glyconanoparticle preparation by microemulsion polymerization 
 
Glyconanoparticles were prepared with a 9:1 (by weight) blend of ethyl acrylate and one of the 
monosaccharide acrylates (20% by weight) by emulsion polymerization (Scheme 2.3). Sodium dodecyl sulfate 
(also known as sodium lauryl sulfate) was used as the surfactant for this preparation and potassium persulfate 
was used as the initiator as the polymerization is in an aqueous system. The structurally diverse monosaccharide 
acrylates derived from glucose, galactose, mannose, ribose and glucosamine ( monomers 1, 2, 3, 4 and 5 
respectively) were used as co-monomers to prepare the corresponding polymeric glyconanoparticles ( GNP1,  
GNP2, GNP3, GNP4 and GNP5 ). Briefly, ultrapure water and sodium dodecyl sulfate (SDS) were added to 
the mixture of monomers, and the mixture was pre-emulsified with stirring under a nitrogen atmosphere. A 
milky colored emulsion (Fig. 2.1) was prepared by adding potassium persulfate to the mixture and stirring at 70 
oC for 6 h. The polymerization conditions are given in Table 2.1.   
 
Scheme 2.3: Preparation of glyconanoparticles by emulsion polymerization 
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Figure 2.4: A vial containing a representative carbohydrate-bearing polyacrylate emulsion.  
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Table 2.1: Formulation used for the emulsion polymerization 
  ___________________________________________________ 
 
  Components   Amounts        Solid Content 
   
  Monosaccharide acrylate    100 mg   9.6% 
  Ethyl acrylate         900 mg  86.5% 
  Sodium dodecyl sulfate      30 mg  2.9% 
  Potassium persulfate       10 mg  1.0% 
  Water         4 mL   
  Reaction temperature       70 o C    
 
 
2.5 Glyconanoparticle characterization 
 
The physicochemical properties of the glyconanoparticles were examined using scanning electron 
microscopy (SEM), dynamic light scattering (DLS) and 1H NMR spectroscopy. Emulsion polymerization of 
differentially O-protected monosaccharide monomers 1-5 showed no significant dependence on the nature of 
the monosaccharide or on the location of the acryloyl moiety. The following chapter describes the 
characterization of glyconanoparticles prepared with 3-O-acryloyl-1,2:5,6-di-O-isopropylidine-α-D-
glucofuranose (1) using these techniques. 
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2.5.1 Scanning Electron Microscopy (SEM) analysis 
 
The morphology and the particle size of the emulsified nanoparticles were examined by scanning 
electron microscopy (SEM). SEM measurements of the glyconanoparticles were captured on a Hitachi S800 
SEM instrument in the USF Department of Engineering. Samples were prepared by placing a drop of diluted 
emulsion (1 µL of emulsion in 30 mL of de-ionized distilled water) on the silicon wafer and evaporating the 
solvent by air blowing prior to coating with gold sputter under high vacuum. The SEM image of 
glyconanoparticles prepared with 3-O-acryloyl-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (1) and ethyl 
acrylate (GNP1) is shown in Figure 2.5. As seen in the image, the nanoparticles were essentially perfectly 
spherical and measured from 20 to 70 nm in diameter. 
 
Figure 2.5:  SEM image of glyconanoparticles prepared from 3-O-acryloyl-1,2:5,6-di-O-isopropylidene-α-D-
glucofuranose (1) and ethyl acrylate by emulsion polymerization ( courtesy:  Dr. J. Y. Shim).  
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2.5.2 Dynamic Light Scattering (DLS) analysis 
 
DLS analyses were performed using a UPA 150 Honeywell MicroTrac DLS instrument equipped with 
a laser beam at 780 nm. The sample was diluted with de-ionized distilled water (0.05 mL of emulsion in 9.95 
mL of water, polymer concentration 0.1% wt) and sonicated for 3 minutes for the analysis. The value is 
expressed in weight-averaged scales as unimode at a scattering angle of 180 o (backscatter) at a temperature of 
25 oC. The particle size distribution of GNP1, obtained by DLS analysis, is shown in Figure 2.6.  The average 
diameter of the glyconanoparticles was 42 nm, with a statistical standard deviation of 9 nm, and the particles 
measured from 15 to 70 nm in diameter. Table 2.2 summarizes the particle size for each one of the polyacrylate 
glyconanoparticles GNP 1-5. 
 
Figure 2.6: Particle size distribution of glyconanoparticles prepared from 3-O-acryloyl-1,2:5,6-di-O-
isopropylidene-α-D-glucofuranose (1) and ethyl acrylate by emulsion polymerization. 
 
 
 
 
Table 2.2: Average particle sizes of glyconanoparticles GNP 1-5 
 
 
Glyconanoparticles Average Particle Size (nm) 
GNP1 
GNP2 
GNP3 
GNP4 
GNP5 
42.3 
40.6 
45.1 
35.2 
44.1 
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wt % 
Diameter (nm) 
2.5.3 1H NMR analysis 
 
1H NMR spectroscopic analysis of each nanoparticle material was performed using a Bruker DPX-250 
spectrometer. To prepare the sample, a film was formed by evaporation of 0.15 ml of the polymer emulsion 
spread on a clean glass surface. The film was dried at room temperature for 24 hrs, and then taken up (swelled) 
in CDCl3 to perform the NMR experiment (Figure 2.7)  
 
Figure 2.7:  Typical 1H NMR spectra of (a) 3-O-acryloyl-1,2:5,6-di-O-isopropylidine-α-D-glucofuranose (1) 
and (b) the glycopolymer obtained from the emulsion after the film formation. 
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Figure 2.7a shows the original 1H NMR spectrum of the carbohydrate acrylate co-monomer, 3-O-acryloyl-
1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (1), while Figure 2.7b shows the 1H NMR spectrum of the 
glycopolymer obtained after polymerization. Notably, the signals of the acryloyl protons (6.42-5.92 ppm in 
Figure 2.7a) have completely disappeared after the polymerization and broad absorptions for the protons H-1, 
H-3 and H-2 (5.90, 5.17 and 4.36 ppm in Figure 2.7b) of the monosaccharide moiety are plainly visible. This 
confirms the complete conversion of the carbohydrate monomer to polyacrylate within the nanoparticle matrix, 
without any detectible amount of residual unreacted monomer. 
 
2.6 Influence of bulky aryl protecting groups in the carbohydrate acrylate monomer on glyconanoparticle 
preparation.  
 
Upon the successful execution of the radical emulsion polymerization process using protected 
manosaccharides 1-5,  these studies were extended to two other O-protected carbohydrate monomers, O-benzyl 
and O-benzoyl protected monosaccharide acrylates 13 and 14 (Figure 2.8). These two carbohydrate acrylate 
monomers bearing bulky aryl protecting groups were synthesized as shown in Schemes 2.4 and 2.5. 
 
Figure 2.8:  1-O-Acryloyl-2,3,5-tri-O-benzyl-β-D-ribofuranose (13) and 2-N-acryloyl-1,3,4,6-tetra-O-benzoyl-
β-D-glucosamine (14). 
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2.6.1 1-O-Acryloyl-2,3,5-tri-O-benzyl-β-D-ribofuranose (13) 
 
Scheme 2.4: Synthesis of 2,3,5-tri-O-benzyl-β-D-ribofuranose-1-acrylate 
 
a
D-ribose
O
HO OH
HO OH
O O
BnO OBn
BnO
O OH
BnO OBn
BnO
O O
BnO OBn
BnO
O
b
c
13
15
16  
 
Conditions: (a) i. H2SO4, methanol; ii. BnBr, NaH, DMF, 77%; (b) 0.1N HCl, Dioxane, 65%; (c) acryloyl 
chloride, Et3N, CH2Cl2, 60%. 
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The synthesis of compound 13 started with D-ribose as shown in scheme 2.4. Using methanolic sulfuric acid, 
the free sugar (D-ribose) was converted to methyl β-D-ribofuranoside44 which afforded methyl 2,3,5-tri-O-
benzyl-β-D-ribofuranoside (15) after benzylation with BnBr in DMF-NaH.45 The product was hydrolyzed in 
dioxane solution with aqueous hydrochloric acid to give 2,3,5-tri-O-benzyl-D-ribose44 (16). Acrylation with 
acryloyl chloride and Et3N in CH2Cl2 then afforded compound 13. 
 
 
2.6.2 N-Acryloyl-1,3,4,6-tetra-O-benzoyl-β-D-glucosamine (14) 
 
Scheme 2.5: Synthesis of N-acryloyl-1,3,4,6-tetra-O-benzoyl-β-D-glucosamine 
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Conditions: (a) BzCl, Py, 71%; (b) acetone, 5M HCl, 87%; (c) acryloyl chloride, Et3N, CH2Cl2, 63%. 
 
As shown in scheme 2.5, compound 14 was synthesized from the intermediate product 10 after benzoylation 
(compound 17), removal of the p-methoxybenzylidene group with HCl in acetone (compound 18) and 
acrylation with acryloyl chloride and Et3N in CH2Cl2. 
 
To my surprise, 1H NMR analysis revealed that the use of these monomers was not as successful in the 
preparation of glyconanoparticles as those from acrylates 1-5, as significant amounts of the unreacted 
carbohydrate acrylates remained after polymerization. The reasons for this outcome are not obvious, but the 
presence of these bulky aryl protecting groups on the sugar monomer may affect its reactivity or radical transfer 
capabilities, and thus induce low incorporation into the polymer backbone. 
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2.7 Influence of free hydroxyl groups of the monosaccharide acrylate monomer on the formation of 
glyconanoparticles. 
 
In direct follow-up to this last set of experiments, additional studies were carried out to investigate 
whether a carbohydrate acrylate having free (unprotected) hydroxyl groups could be used directly for the 
nanoparticle formation. This was first studied with 3-O-acryloyl-D-glucose (19) (Scheme 2.6), the deprotected 
form of acrylate 1 prepared by treating compound 1 with 90% trifluoroacetic acid. The emulsion prepared with 
19 and ethyl acrylate as a co-monomer appeared much less transparent to the eye than the emulsion prepared 
with the relevant protected monomer, 3-O-acryloyl-1,2:5,6-di-O-isopropylidene-α-D-glucofuran-ose (1), using 
the same formulation. In fact, DLS analysis of the emulsion indicated the average particle size was around 85 
nm in diameter, about double the size of the particles prepared from the O-protected acrylate 1. We obtained 
similar results with the emulsions prepared with 5-O-acryloyl-1-methoxy-β-D-ribofuranose (20) (Scheme 2.6) 
versus 5-O-acryloyl-2,3-O-isopropylidene-1-methoxy-ß-D-ribofuranose (5).  
 
Scheme 2.6: Deacetonation of carbohydrate acrylates 1 and 5. 
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Conditions: (a) 90% CF3COOH, rt, 30 min., 90%; (b) 80% CH3COOH, 80 oC, 2 hrs, 68% 
 
 
The photographic images in Fig. 2.9a show the increasing turbidity of the emulsions as the 
concentration of acrylate monomer 20 is increased from 5% (E2) to 7.5% (E3) to 10% (E4) of the monomer 
content, relative to the appearance of the emulsion E1 prepared with fully protected monomer 5 (having 10% 
carbohydrate by weight relative to ethyl acrylate). Dynamic light scattering data confirms that this increasing 
cloudiness in the emulsions is due to larger glyconanoparticle formation (Fig. 2.9b) as the amount of 
unprotected carbohydrate monomer is increased from 5% (E2) to 10% (E4). This suggests that nanoparticle size 
may be dependent on the presence and the degree of hydrogen-bonding effects within the carbohydrate moiety 
while the polymeric matrix is being formed. 
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Figure 2.9: Comparison of the effects of using an O-protected versus O-unprotected monosaccharide acrylate 
on nanoparticle size. (a) Photographs of four different emulsion samples prepared with 20% (by weight) 
polymer content from 5-O-acryloyl-2,3-O-isopropylidene-1-methoxy-ß-D-ribofuranose (5) and 5-O-acryloyl-1-
methoxy-β-D-ribofuranose (20) as co-monomers with ethyl acrylate. E1: monomer 5 and ethyl acrylate (1:9 by 
weight). E2: monomer 20 and ethyl acrylate (1:19 by weight). E3: monomer 20 and ethyl acrylate (1:14 by 
weight). E4: monomer 20 and ethyl acrylate (1:9 by weight); (b) Average particle sizes of these formulations 
from DLS analysis. 
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2.8 Nucleoside-bearing polyacrylate nanoparticles 
 
Nucleosides are a well-studied class of drugs useful for treating viral infections and leukemia. In most 
cases, inhibition of viral replication and cell proliferation is associated with intracellular conversion of 
nucleosides to nucleoside triphosphates, which act as either inhibitors of viral and cellular DNA and RNA 
polymerases or as chain terminators following incorporation into a growing DNA or RNA strand46. 
Experiments were done to investigate whether nucleoside-bearing polyacrylate nanoparticles could be prepared 
for potential further biological evaluation, using acrylated cytidine analogue 23 (Scheme 2.7).  
 
 
2.8.1 4-N-Acetyl-5’-O-acryloyl-2’,3-O-isopropylidenecytidine 
 
Scheme 2.7: Synthesis of 4-N-acetyl-5’-O-acryloyl-2’,3-O-isopropylidenecytidine 
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Conditions: (a) i. p-TsOH, acetone ii. aq. NaHCO3, 60%; (b) Ac2O, methanol, reflux, 86%; (c) acryloyl 
chloride, Et3N, CH2Cl2, 60%. 
 
2’,3’-O-Isopropylidene cytidine  (21) was prepared from cytidine using p-toluenesulfonic acid in acetone.47 
Treatment of compound 21 with acetic anhydride in methanol afforded 4-N-acetyl-2’,3’-O-isopropylidene 
cytidine48 (22) which was acrylated to give compound 23. Monomer 23 was polymerized in microemulsion and 
cytidine functionalized polyacrylate nanoparticles were prepared. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
2.9 Conclusions 
 
In this chapter, the first preparation of polyacrylate nanoparticles bearing carbohydrates within the 
polymeric framework by emulsion polymerization was demonstrated. The glyconanoparticles displayed narrow 
size distributions in the range of 20-70 nm. Acetonide and acetyl protected monosaccharide acrylates were 
found to be well suited for this preparation as proton NMR analysis of the relevant emulsions indicated 
essentially 100% incorporation of the carbohydrate acrylate monomer into the polymer. An increase of the 
particle size was observed upon use of 3-O-acryloyl-D-glucose (19) and 5-O-acryloyl-1-methoxy-β-D-
ribofuranose (20) as monomers bearing free hydroxyl groups. This methodology allows for a new, simple route 
to the synthesis of polymeric glyconanoparticles with potential applications in drug delivery and materials 
development. Also nucleosides can be used for this preparation and it may open potential avenues to using 
nucleoside-bearing nanoparticles as nucleic acid transporters.49 The next chapter will describe the use of these 
glyconanoparticles as drug delivery vehicles for various antibiotics and their biological activity. 
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CHAPTER III 
 
GLYCONANOBIOTICS: SYNTHESIS AND BIOLOGICAL ACTIVITY 
 
 
3.1 Introduction 
 
 The use of nanoparticles in medicine is one of the important directions that nanotechnology is taking at 
this time. Their application in drug delivery,50-52 cancer cell diagnostics,53-56 and therapeutics57 have been active 
fields of research. The use of nanoparticles as drug delivery systems is of particular interest because they have 
some advantages such as easy purification and sterilization, drug targeting possibilities, and sustained release 
action.58-59 However, the use of nanoparticles as drug delivery vehicles in the field of antibiotic therapy has 
received relatively little attention. 60-61 The Turos group recently reported the formation of antibiotic-conjugated 
polyacrylate nanopaticles as a water solubility enhancer for antibiotics having extremely low water solubility. In 
this process, the antibiotic is converted to an acrylated derivative with the reaction of acryloyl chloride and then 
used as a co-monomer with styrene/butyl acrylate mixture in microemulsion polymerization. To dissolve the 
antibiotic drug monomer in the styrene/butyl acrylate co-monomeric mixture to homogeneity is an important 
step of this preparation to avoid incomplete drug incorporation into the polymer backbone. N-Thiolated β-
lactam acrylated monomers such as 24 (Fig. 3.1) were found to be well suited to prepare nanoparticle 
antibiotics, or nanobiotics, by emulsion polymerization. However, when Dr. Suresh Reddy and Kerriann 
Greenhalgh in the Turos group tried to extend this protocol to other classes of antibiotics, such as penicillin and 
ciprofloxacin, the corresponding monomers (25 and 26 in Fig. 3.1) obtained from the reaction of acryloyl 
chlorides showed extremely low solubility in styrene/butyl acrylate. This resulted in much of the drug monomer 
being unreacted after the polymerization. Hence, it was felt that more lipophilic drug monomers are needed for 
this preparation. 
 
Figure 3.1: Structures of acrylated antibiotic monomers of N-thiolated β-lactam (24), penicillin (25) and 
ciprofloxacin (26). 
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 Although monosaccharides are well known for their hydrophilicity due to the presence of free 
hydroxyl groups, their protected forms are hydrophobic. The conjugation of an acrylated hydrophobic moiety to 
the lipophilic antibiotic will make it even more lipophilic and suitable as a co-monomer in microemulsion 
polymerization. This idea led to the aim of preparing novel carbohydrate-based acrylated acyl chlorides to 
synthesize carbohydrate conjugated drug monomers. This chapter describes the synthesis of novel 
carbohydrate-based reagents to prepare carbohydrate-conjugated drug monomers, and the microemulsion 
polymerization of these monomers to prepare glyconanoparticle antibiotics, or glyconanobiotics. The biological 
activity of the drug monomers and the glyconanobiotics derived from them is also discussed. 
 
 
3.2 Synthesis of novel carbohydrate-based acyl chlorides 
 
 For these exploratory investigations, two glucose-based acrylated acyl chlorides (27 and 28)  shown in 
Fig. 3.2 were synthesized and used in place of acryloyl chloride to prepare carbohydrate-conjugated antibiotic 
monomers for the emulsion polymerization (to be described).  
 
Figure 3.2: Structures of diacyl chloride 27 and acyl chloride 28. 
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3.2.1 3-O-Acryloyl-1,2-O-isopropylidene-5,6 bis((chlorosuccinyl)oxy)-D-glucofuranose (27) 
 
 The first of these acrylated acid chlorides, compound 27, was prepared in three steps from protected 
glucose acrylate 1 (Scheme 3.1). 
 
Scheme 3.1: Synthesis of 3-O-Acryloyl-1,2-O-isopropylidene-5,6 bis((chlorosuccinyl)oxy) 
        -D-glucofuranose (27) 
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Conditions: (a) 80% CH3COOH, 80 oC, 4h, 62% ; (b) succinic anhydride, Et3N, CH2Cl2, 25 oC, 5h, 65%; (c) 
SOCl2, 25 oC, 3h, 98%. 
 
Partial deacetonation of acrylate monomer 1 with 80% acetic acid at 80 oC and conjugation of the product 29 
with succinic anhydride in the presence of Et3N and dry dichloromethane afforded the diacid 30 in 40% overall 
for the two steps.  Thionyl chloride was used to convert compound 30 to the corresponding diacyl chloride 27. 
While diacid 30 was characterized by 1H NMR, diacyl chloride 27 was used without purification. 
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3.2.2 6-O-Acetyl-3-O-Acryloyl-1,2-O-isopropylidene-5-((chlorosuccinyl)oxy)-D-glucofuranose (28) 
 
 Scheme 3.2 describes the synthesis of acrylated acyl chloride 28. Selective acylation of the 
primary hydroxyl group of the diol62 29 was achieved in 72% yield with acetyl chloride in dichloromethane 
in the presence of 2,4,6-collidine to give  compound 31. Acyl chloride 28 was obtained in two steps via 
acid 32 in a similar procedure to that described in Scheme 3.1. 
 
Scheme 3.2: Synthesis of 6-O-acetyl-3-O-acryloyl-1,2-O-isopropylidene-5-((chlorosuccinyl)oxy)-D-
glucofuranose (28) 
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Conditions: (a) collidine, AcCl, CH2Cl2, -40 oC, 3h, 72%; (b) succinic anhydride, Et3N, CH2Cl2, 25 oC, 5h, 
64%; (c) SOCl2, 25 oC, 3h, 98%.  
 
 
3.3 Synthesis of novel antibiotic-conjugated carbohydrate monomers 
 
 
3.3.1 N-Thiolated β-lactam-conjugated glucose acrylate (34) 
 
 N-Thiolated β-lactams discovered in the Turos group are a new family of antibacterial agents 
active against Staphylococcus bacteria, including methicillin-resistant strains of Staphylococcus aureus 
(MRSA) 63-64, and Bacillus anthracis 65 which is the causative agent of anthrax infections. These 
compounds have a mode of action distinct from that of all other β-lactam antibiotics.63 Rather than 
interfering directly with cell wall biosynthesis through irreversible acylation of penicillin binding 
transpeptidases, these compounds seem to affect cellular processes through transfer of the N-organothio 
group to a bacterial thiol.65 For the goal of preparing nanoparticle variants of this class of antibacterial 
agents, bis-N-thiolated lactam glucose acrylate 34 was selected as a target. 
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 Monomer 34 was synthesized from N-sec-butylthio β-lactam derivative66 33 by coupling with 
diacyl chloride 27 and Et3N in CH2Cl2 as shown in Scheme 3.3. The yield for the coupling was 62%. 1H 
NMR and ESI-MS spectra of compound 34 are shown in Fig. 3.3 and Fig. 3.4 respectively. 
 
Scheme 3.3: Synthesis of N-sec-butylthio β-lactam monomer 34 
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Figure 3.3:  1H NMR spectrum of N-sec-butylthio β-lactam monomer 34  
 
 
 
 
Figure 3.4: ESI-MS spectrum of N-sec-butylthio β-lactam monomer 34  
      (m/z 1028.3 [M+NH4]+, Calcd. 1028.0) 
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3.3.2 Ciprofloxacin-conjugated glucose acrylates (36 and 37) 
 
 Anthrax, an infectious disease caused by the bacterium Bacillus anthracis, poses a significant 
threat to the public as a bioterrorist agent. Ciprofloxacin is a fluoroquinolone antibiotic that is commonly 
used to treat anthrax infections. Its mode of action depends upon blocking bacterial DNA replication by 
binding  to an enzyme called DNA gyrase, thereby causing double-stranded breaks in the bacterial 
chromosome.67 
 
 In concert with the previously stated objective of preparing antibiotic-conjugated polyacrylate 
nanoparticles, bis-ciprofloxacin and mono-ciprofloxacin glucose acrylates 26 and 27, respectively, were 
chosen as potential monomers for the emulsion polymerization. Ciprofloxacin-conjugated monomers 36 
and 37 were synthesized by coupling with diacyl chloride 27 and acyl chloride 28 respectively and Et3N in 
CH2Cl2 (Schemes 3.4 and 3.5). The coupling occurred in over 50% yield in each case. 
 
Scheme 3.4: Synthesis of bis-ciprofloxacin monomer 36 
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Scheme 3.5: Synthesis of mono-ciprofloxacin monomer 37 
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1H NMR and ESI-MS spectra of compound 37 are shown in Fig. 3.5 and Fig. 3.6 respectively. 
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Figure 3.5:  1H NMR spectrum of mono-ciprofloxacin monomer 37 
 
 
 
 
 
Figure 3.6: ESI-MS spectrum of mono-ciprofloxacin monomer 37  
      (m/z 752.2 [M+Na]+, Calcd. 752.6) 
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3.3.3 Penicillin-conjugated glucose acrylate 
 
 Penicillin is one of the earliest discovered and widely used antibiotic agents, derived from the 
Penicillium mold. The antibacterial effect of penicillin was discovered by Sir Alexander Fleming in 1929. 
Penicillin derivatives produce their bacteriocidal effects by inhibiting the formation of peptidoglycan cross 
links in the bacterial cell wall. 68 The β-lactam moiety of penicillin binds to the enzyme (transpeptidase) 
that links the peptidoglycan molecules in bacteria, and this weakens the cell wall of the bacterium when it 
multiplies (in other words, the antibiotic causes cytolysis or death when the bacterium tries to divide). 
 
 Although β-lactam antibiotics such as penicillin G have been mainstays of clinical treatment for 
many types of bacterial infections, their effectiveness has been compromised by the ability of drug-resistant 
bacteria to produce β-lactamase enzymes that hydrolyze the β-lactam moiety in these antibiotics to render 
them inactive.  The studies in the Turos lab have revealed that penicillin-bound polyacrylate nanoparticles 
prepared by microemulsion polymerization are able to recover the in vitro antibacterial activity of penicillin 
against β-lactamase-producing MRSA.69 
 
 Penicillin-conjugated monomer 40 was synthesized from 6-aminopenicillanic acid (38) via its 
trimethylsilyl ester 39, which was then reacted with acyl chloride to give 40 in 51% yield (Scheme 3.6). 
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Scheme 3.6: Synthesis of penicillin-containing acrylate monomer 40 
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3.4 Glyconanobiotics by emulsion polymerization 
 
Scheme 3.7: Preparation of glyconanobiotics by emulsion polymerization 
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Glyconanoparticle antibiotics, or glyconanobiotics, were prepared from the above-described 
antibiotic-conjugated carbohydrate monomers and a blend of styrene/butyl acrylate (3:7 w/w) by 
microemulsion polymerization  using sodium dodecyl sulfate (3% w/w) and potassium persulfate (1% w/w) 
as the surfactant and the initiator, respectively (Scheme 3.3). The general procedure involved dissolving the 
drug monomer in the mixture of styrene/butyl acrylate and pre-emulsifying the mixture in purified water 
containing sodium dodecyl sulfate with stirring under a nitrogen atmosphere. Then the emulsion was 
prepared by adding potassium persulfate to the mixture and stirring at 70 oC for 6 hours. The 
polymerization conditions used to prepare GNB34, GNB37 and GNB40 are given in Table 3.1. GNB 36 
could not be made, however, because the bis-ciprofloxacin monomer 36 was not soluble in the mixture of 
styrene/butyl acrylate. 
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Table 3.1: Formulation used for the emulsion polymerization to prepare antibiotic-conjugated           
                  glyconanoparticles GNB 34, GNB 37, and GNB 40. 
                              
  ___________________________________________________ 
 
  Components   Amounts        Solid Content 
   
  Drug monomer       20 mg    2% 
  Butyl acrylate         658 mg  65.8% 
  Styrene    282 mg  28.2% 
  Sodium dodecyl sulfate      30 mg    3% 
  Potassium persulfate       10 mg    1% 
  Water         4 mL   
  Reaction temperature      70 o C    
 
 
These glyconanobiotics displayed a highly controlled particle diameter of about 40 nm, and 
possessed antibacterial activity by virtue of having an antibiotic compound covalently bound within the 
matrix. It is curious that under these conditions the particle size is not significantly changed even though 
the properties of the antibiotic monomers are dramatically different. Table 3.2 summarizes the particle size 
for each prepared glyconanobiotic GNP 34, GNP37, and GNP40.  
 
 
Table 3.2: Average particle sizes of glyconanoparticles GNP 34, GNP37, and GNP40 as determined by           
                  dynamic light scattering. 
 
Glyconanobiotic Average Particle Size (nm) 
 
GNB34 
GNB37 
GNB40 
 
 
38.9 
45.1 
43.4 
 
 
 
3.5 Biological activity  
 
 The antimicrobial activity of the antibiotic-conjugated carbohydrate monomers and their 
corresponding emulsions (glyconanobiotics) were determined by measuring the minimum inhibitory 
concentration, or MIC, values in broth media. MIC determination is an accepted method for assessing 
antimicrobial activity of compounds. This method is an aqueous phase technique where bacteria, nutrients 
and antibiotic candidates are all suspended in solution together. The minimum amount of compound 
required to completely inhibit visible bacterial growth is the MIC value for that compound. The lower the 
MIC, the stronger the compound’s bioactivity. The bacterial growth is examined optically for changes in 
opacity due to increasing cell counts. 
 
 The monomers and the emulsions were individually tested for antibacterial activity against 
Staphylococcus aureus (S. aureus), a strain of methicillin-resistant Staphylococcus aureus (MRSA) and 
Bacillus anthracis (B. anthracis).  S. aureus and MRSA microbes were purchased from American Type 
Culture Collections (ATCC). 
 
 
 
 
 
 
37 
3.5.1 Biological activity of antibiotic monomers 34, 36, 37, and 40 against S. aureus, MRSA and B.   
         anthracis 
 
 The minimum inhibitory concentration (MIC) values for the antibiotic monomers 34, 36, 37 and 
40 are summarized in Table 3.2.  Since compound 34 was not readily miscible in broth media, the MIC 
values were obtained by agar plate dilution. For the monomers 36, 37, and 40, the MIC values were 
obtained in broth media. N-Thiolated β-lactam-conjugated acrylate 34 and ciprofloxacin-conjugated 
acrylates 36 and 37 showed significant activity against S. aureus, MRSA and B. anthracis, while the 
penicillin monomer 40 had no in vitro activity against these three microbes. Bis-ciprofloxacin monomer 36 
showed higher activity against S.aureus and MRSA than the mono-ciprofloxacin monomer 37, whereas the 
respective activities against B. anthracis were reversed.  
 
Table 3.3: MIC values for antibiotic-conjugated carbohydrate monomers 
 
Monomer S.aureus 
(ATCC 25923) 
MRSA 
(ATCC 43300) 
B. anthracis 
 
34 
36 
37 
40 
 
126 nM 
  30 nM 
  44 nM 
     > 393 nM 
 
126 nM 
  30 nM 
  44 nM 
    > 393 nM 
 
63 nM 
60 nM 
22 nM 
   > 393 nM 
 
 
3.5.2 Biological activity of glyconanobiotics GNB 34, GNB 36, and GNB 40 against S. aureus, MRSA  
         and B. anthracis 
 
 The same in vitro experiments were run for GNB 34, GNB 36, and GNB 40. MIC values of these 
glyconanobiotics are shown in Table 3.3 and the inactive penicillin monomer 40 proved to generate 
inactive glyconanobiotics after polymerization 
 
Table 3.4: MIC values for glyconanobiotics 
 
 The glyconanobiotic GNB 36 showed the same activity profile against S. aureus, MRSA and B. 
anthracis as the relevant ciprofloxacin monomer 36. The N-thiolated β-lactam glyconanobiotic GNB 34 
tested in broth media showed higher activity against S. aureus and MRSA than the β-lactam monomer 34. 
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Glyconanobiotic S.aureus 
(ATCC 25923) 
MRSA 
(ATCC 43300) 
 
B. anthracis 
 
GNB 34 
GNB 36 
GNB 40 
 
 63 nM 
 44 nM 
   > 393 nM 
 
 63 nM 
  44 nM 
    > 393 nM 
 
63 nM 
22 nM 
   > 393 nM 
3.6 Conclusions 
 
 Novel carbohydrate-based acrylated acyl chlorides 27 and 28 were synthesized from glucose and 
used in place of acryloyl chloride to prepare carbohydrated antibiotic drug monomers 34, 36, 37, and 40. 
These antibiotic-conjugated carbohydrate monomers were polymerized in microemulsion with 
styrene/butyl acrylate to prepare glyconanoparticle antibiotics (glyconanobiotics). The monomers and 
corresponding glyconanobiotics showed biological activity against S. aureus, MRSA and B. anthracis 
microbes. This development of antibiotic-laden glyconanoparticles demonstrates for the first time the use 
of the polymeric glyconanoparticles as drug delivery vehicles. The next chapter will discuss the use of 
these glycosylated nanoparticles as recognition units in carbohydrate ligand mediated targeted drug 
delivery. 
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CHAPTER IV 
 
PREPARATION OF POLYACRYLATE GLYCONANOPARTICLES WITH SURFACE 
CARBOHYDRATES 
 
 
4.1 Introduction 
 
 Glycotargeting, the use of carbohydrate ligands to bind selectively to protein receptors, is a 
promising approach in targeted drug delivery. Glycotargeting relies on carrier molecules possessing 
carbohydrates that are recognized and internalized by cell surface mammalian lectins. Numerous types of 
glycotargeting vehicles have been designed based on the covalent attachment of saccharides to proteins, 
polymers and other aglycones.  These carriers have found their major applications in antiviral therapy, 
immunoactivation, enzyme replacement therapy and gene therapy.70 
 
 To investigate the use of polyacrylate glyconanoparticles in ligand-mediated targeted drug 
delivery as shown in Fig. 4.1, study was undertaken to prepare and characterize new polyacrylate  
nanoparticles whose surfaces are modified with carbohydrates.  The binding ability of these 
glyconanoparticles was evaluated by fluorescence spectroscopy with the use of sugar-binding boronic 
acids. This chapter describes the preparation of two glucose-functionalized polyacrylate nanoparticles as 
prototypes (Fig. 4.2), using emulsion polymerization as described in the previous chapter, and the 
characterization of the physical properties. 
 
Figure 4.1: A cartoon showing the use of carbohydrate ligands to target protein receptors (curly structures) 
in targeted drug delivery to bacterial cell. 
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Figure 4.2: Glucose-functionalized polyacrylate nanoparticles with (a) short and (b) long tether lengths. 
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4.2 Preparation of acrylated glucose monomers 
 
 Two acrylated glucose monomers with different tether lengths (Fig. 4.3) were used to prepare these 
glyconanoparticles by microemulsion polymerization with styrene/butyl acrylate.  Monomer 19, 3-acryloyl-D-
glucose, can be prepared by deacetonation of monomer 1 as previously described in scheme 2.6. Monomer 41, 
with a long-chain acrylic moiety, was synthesized from acrylic acid as shown in scheme 4.1.  
 
Figure 4.3: Acrylated D-glucose monomers 
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Scheme 4.1: Synthesis of monomer 41 
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Conditions: (a) NaOH , 90 %; (b) 11-bromoundecan-1-ol, n-tetrabutylammonium bromide, 2,6-di-t-butyl-4-
methylphenol, water, chloroform, 100 oC, 3 days, 58%; (c) succinic anhydride, Et3N, CH2Cl2, 25 oC, 5h, 
80%;(d) diacetone-D-glucose, EDCI, DMAP, CH2Cl2, 75%; (e) 90% CF3COOH, 30 min., rt, 67%.  
 
11-Acryloyloxy undecan-1-ol (44) was prepared from acrylic acid (42) according to a procedure 71 that used 1 
eq. of sodium hydroxide to prepare sodium acrylate (43) which was reacted with 11-bromoundecan-1-ol to give 
compound 44. Conjugation of the product 44 with succinic anhydride in the presence of Et3N and dry 
dichloromethane afforded the acrylated acid 45, and compound 46 was obtained from EDCI coupling of the 
product 45 with diacetone-D-glucose. Deacetonation of compound 46 with 90% trifluoroacetic acid afforded the 
acrylate 41. 
 
 
4.3 Microemulsion polymerization of acrylated glucose monomers 
 
 
Glycosylated polyacrylate nanoparticles, bearing free sugar hydroxyl groups, were prepared with a 9:1 
(by weight) blend of styrene/butyl acrylate and one of the monomers (20% by weight) by emulsion 
polymerization (Scheme 4.1). The polymerization conditions are given in Table 4.1 and the same emulsion 
polymerization procedure was used for this preparation as for the preparations of glyconanoparticles in chapter 
II and glyconanobiotics in chapter III using sodium dodecyl sulfate and potassium persulfate as the surfactant 
and initiator, respectively, in nano-pure water at 70 oC. 
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Scheme 4.2: Preparation of glyconanoparticles with surface carbohydrates by emulsion polymerization.  
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Table 4.1: Formulation used for the emulsion polymerization to prepare glyconanoparticles with surface 
     Carbohydrates 
  ___________________________________________________ 
 
  Components   Amounts        Solid Content 
   
  Carbohydrate monomer    100 mg    9.6 % 
  Butyl acrylate         630 mg  60.5 % 
  Styrene    270 mg  25.9 % 
  Sodium dodecyl sulfate      30 mg    3 % 
  Potassium persulfate       10 mg    1 % 
  Water         4 mL   
  Reaction temperature      70 o C    
 
 
 The monomers having a short-chain acrylic moiety (19) and a long-chain acrylic moiety (41) were 
polymerized in microemulsions to prepare  glyconanoparticles GNP 19 and GNP 41. GNP 19 is less 
transparent than GNP41, and dynamic light scattering analysis revealed larger nanoparticles for GNP 19 as 
shown in Table 4.2. The formation of larger nanoparticles could be due to the swelling of polymer as a result of 
hydrogen-bonding.  
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Table 4.2: Average particle sizes of glyconanoparticles 
 
 
Glyconanoparticle Average Particle Size (nm) 
 
GNP 19 
GNP 41 
 
 
66.2 
34.1 
 
 
 
4.4 Detection of the binding ability of glyconanoparticles   
 
 After the preparation of glyconanoparticles GNP 19 and GNP 11 from monomers 19 and 41, the 
surface availability of the carbohydrate moiety to bind with an external molecule was studied for the potential 
use of these glyconanoparticles as recognition units in carbohydrate-ligand mediated targeted drug delivery. 
Sugar-binding boronic acids were used for this purpose, as described in the following sections.  
 
 
4.4.1 Sugar detection by boronic acids 
 
 The use of boronic acids is regarded as one of the most reliable approaches for the detection and 
quantification of free carbohydrates in water. 72-75 The equilibrium involved between the boronic acid and 
carbohydrates is shown in Scheme 4.2. Boronic acids are electron deficient Lewis acids having a sp2-hybridized 
boron atom with a planar trigonal conformation.76 Boronic acids form fast and reversible covalent interactions 
with soluble carbohydrates. This complexation involves the coordination of vicinal diol groups to the boronate, 
causing displacement of the two alkoxy ligands on boron to make a new boronate derivative. In water, this 
species exists preferably as an anionic boronate. The anionic boronate is highly electron rich and possesses an 
sp3-hybridized boron atom with a tetrahedral conformation (Scheme 4.2). When the boronic acids are 
conjugated with a fluorophore, the neutral form of the boron group acts as an electron-withdrawing group while 
the anionic form acts as an electron-donating group. 77 This change in the electronic properties of the boron 
group leads to spectral changes of the fluorophore, a phenomenon that has been used for the development of 
fluorescent carbohydrate sensors.77-78 Hence, water-soluble boronic acids that change their fluorescence 
properties upon sugar binding are especially useful as reporter units as sensors for carbohydrates. Also, 
carbohydrate-sensitive boronic acids can be used as quenchers to modulate the emission of a variety of dyes 
have been developed. These quencher/dye combinations would thus serve as signal transducers for the detection 
and quantification of sugars.  
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Scheme 4.3: Equilibrium established between the aryl boronic acid and a carbohydrate; and its            
dependency on pH.79 
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 The detection of carbohydrate functionality on the surface of glyconanoparticles GNP 19 and GNP 41 
was attempted for the purpose of showing that carbohydrate moieties built into the polyacrylate backbone 
occupy at least some of the surface area of the nanoparticle, and that it may be possible to ultimately quantify 
this. These studies were done by utilizing the combination of 4,4’-N,N-bis(benzyl-2-boronic acid)-bipyridinium 
dibromide (o-BBV, 48) and (trisodium 8-hydroxy-1,3,6-pyrenetrisulfonate) pyranine (47) (Figure 4.4). o-BBV 
is a boronic acid modified quencher of pyranine 47,  a commercially available , water soluble, anionic dye that 
can be excited by visible light and fluoresces with high quantum yield. 80 This quencher/dye combination 
operates in aqueous solution at pH 7.4, and has been reported to be highly sensitive in detecting glucose in 
aqueous media in the range of 0-1800 mg/dL (glucose concentration). 81    
 
Figure 4.4: Pyranine (47) and o-BBV (48) 
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4.4.1.1 4’,4’-N’,N’-bis(benzyl-2-boronic acid)-bipyridinium dibromide (o-BBV) 
 
 o-BBV (48) was synthesized in two steps from o-tolylboronic acid (49) as shown in Scheme 4.2. 
Radical-induced bromination of compound 49 was carried out using N-bromosuccinimide in the presence of 
2,2’-azobisisobutyronitrile (AIBN) in carbon tetrachloride to give o-bromomethylphenylboronic acid82 (50) 
which afforded o-BBV (48) after refluxing with anhydrous methanol  (to prepare dimethyl-(2-bromomethyl)-
benzeneboronate intermediate)  and reacting with 4,4’-dipyridyl.81 
 
Scheme 4.4: Synthesis of 4’,4’-N’,N’-bis(benzyl-2-boronic acid)-bipyridinium dibromide (o-BBV) 
 
 
N NB B
HO
OH
OH
HO
B
OHHO
B
OHHO
Br
2Br
a b
48
49 50
 
 
 
Conditions: (a) NBS, AIBN, CCl4, reflux, 2 hrs, 50 %; (b) i. methanol, reflux; ii. 4,4’-dipyridyl, 63%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
4.4.2 Studies on the binding of o-BBV to 3-acryloyl-D-glucose 
 
 Having synthesized the boronic acid-modified quencher, o-BBV, fluorescence studies were then 
carried out to investigate whether 3-acryloyl-D-glucose (19) can bind to o-BBV as shown in Scheme 4.3. 
Addition of 5 mg/mL of 3-acryloyl-D-glucose in pH 7.4 phosphate buffer to an aqueous solution of o-BBV 
(3X10-4 M) and pyranine (1X10-5 M) led to a 17% signal increase in fluorescence intensity at λmax = 517 nm ( 
λmax = 511 nm has been  reported in the literature), as plotted in Fig. 4.5. This shows that this quencher/dye 
combination is highly sensitive not only to glucose81 but also to 3-acryloyl-D-glucose (19).  
 
Scheme 4.5: Reversible complexation reaction of o-BBV/3-acryloyl-D-glucose. 
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Figure 4.5: Fluorescence spectra of pyranine (1X10-5 M, excitation = 461.8 nm, emission λmax = 517 nm) in 0.1 
ionic strength aqueous phosphate buffer (pH 7.4) (■ - pyranine with o-BBV ( 1X10-4 M) ;   ▲ - pyranine with o-
BBV ( 1X10-4 M) and 3-acryloyl-D-glucose (5 mg/mL).  
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4.4.3 Studies on the binding of o-BBV to glyconanoparticles 
 
 Having established the sensing ability of pyranine/o-BBV complex towards 3-acryloyl-D-glucose (19), 
the same experiment was repeated for the glyconanoparticles (GNP 19 and GNP 41) as shown in Scheme 4.4.  
 
Scheme 4.6: Binding of glyconanoparticles with o-BBV 
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* prepared at 70 oC according to the formulation: butyl acrylate – 700 mg  , styrene – 300 mg ,  sodium dodecyl sulfate – 30 mg , potassium      
persulfate – 10 mg and water – 4 mL.  
 
 
 In this case, a 27% enhancement of fluorescence intensity (Figure 4.6) was observed upon mixing a 
solution of GNP 19 with pyranine/o-BBV complex against a solution of nanoparticles* prepared with 
styrene/butyl acrylate. Prior to the experiments, the nanoparticle emulsions were centrifuged at 12000-13000 
rpm (16100 X g) for 30 minutes to remove any solid polymer materials formed during the emulsion 
polymerization, and then dialyzed (membrane, 6000-8000 MWCO) overnight in de-ionized water in order to 
remove excess surfactants. o-BBV binding studies were performed by adding 1.00 mL of emulsion (GNP 19 or 
GNP 41) to 4.00 mL of pyranine (1X10-5 M) /o-BBV(1X10-4 M) solution at pH 7.4.   
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Figure 4.6: Fluorescence spectra of pyranine (8X10-6 M, excitation = 461.8 nm) in 0.1 ionic strength aqueous 
phosphate buffer (pH 7.4) (■ - pyranine with o-BBV (8X10-5 M) and emulsion* (20% by vol.) prepared with 
styrene/butyl acrylate;   ▲ - pyranine with o-BBV (8X10-5 M) and GNP 19 (20% by vol.; 5 mg/mL of 19). 
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 By changing the system from pyranine (1X10-5 )/ o-BBV (1X10-4 M) to  pyranine (8X10-6 )/ o-BBV 
(8X10-5 M)/ emulsion* (20% by vol.) with a 20% dilution of the dye/quencher mixture, only 2% signal increase 
of the fluorescence intensity was observed. This increase could be due to the interaction of negatively charged 
polyacrylate nanoparticles to positively charged o-BBV, lowering the quenching ability. Therefore, a 27% 
fluorescence enhancement from GNP 19 relative to the emulsion* (prepared with styrene/butyl acrylate) 
indicates the presence of a binding interaction of a surface sugar with o-BBV. Curiously, a relative fluorescence 
enhancement could not be observed upon using GNP 41 with the o-BBV/pyranine system. This may indicate 
that the highly lipophilic monomer 41 could allow for the entrapment of the carbohydrate moiety inside the 
nanoparticle during the polymerization, making it unavailable on the surface.  
 
 As these studies revealed that the surface charge of the glyconanoparticle can affect the fluorescence 
intensity of dye/quencher systems, it may not be recommended that the boronic acid salts be used as reporter 
units in future quantification studies involving these anionically-charged nanoparticles. Instead, the water-
soluble boronic acids, such as dibenzofuran-4-boronic acid (Figure 4.7) which exhibits unique fluorescence 
changes at three wavelengths upon binding with sugars in water83, may be more suitable for this purpose.  
 
Figure 4.7: Dibenzofuran-4-boronic acid 
 
 
                                     
O B
HO
OH
 
 
 
 In conclusion, polymeric glyconanoparticles with surface-exposed carbohydrates have been prepared 
by microemulsion polymerization with 3-acryloyl-D-glucose. Carbohydrate monomers with longer tether 
lengths, such as monomer 41, do not appear to be suitable for this preparation due to the higher lipophilicity.  
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4.5 Conclusions and future work 
 
 Throughout various fields of science and technology, a push towards the use of nano-scale technology 
is well underway. One area where nano-scale work is already prominent is within the field of drug delivery. The 
preparation of glyconanoparticle antibiotics, or glyconanobiotics, allows the Turos group to expand to other 
classes of antibiotics with poor lipophilicity.  
 
 One of the key features of these glycosylated polyacrylate nanoparticles is their binding ability with 
boronic acids, which may allow for novel applications in carbohydrate-ligand mediated targeted drug delivery. 
Also, this feature makes these glyconanoparticles ideal candidates for cancer therapy as ‘plug drugs’ (drugs 
which fit into the active sites) as researchers have shown that a significant link exists between the presence of 
carbohydrates on the cancer cell surface and their metastatic potential (capacity to spread around the body).  
Furthermore, functionalization of glyconanoparticles has been demonstrated for the first time, through the 
binding of the surface-exposed carbohydrates with water-soluble boronic acid salts. This may offer a 
straightforward, simple, synthetic pathway for the development of novel functionalized nanomaterials as shown 
in Figure 4.8. The designing of nanoparticles of different sizes could be useful for applications in cavitation-
mediated drug delivery for cancer treatments. 84 Efficacy and safety of cancer chemo-and biotherapy are limited  
 
Figure 4.8: Post-functionalization of glyconanoparticles 
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by poor penetration of anti-cancer drugs from blood into tumor cells. Tumor blood vessel wall and cancer cell 
membrane create physiological barriers for anti-cancer drugs, in particular, promising macromolecular agents. 
The nanoparticles selectively delivered in tumor blood vessels can serve as nuclei for formation of cavitation 
microbubbles upon ultrasound irradiation. The interaction of the nanoparticles with the ultrasound results in 
cavitation (formation, growth, and collapse of microbubbles).  The ultrasound induced cavitation is 
accompanied by strong local hydrodynamic flows, which can produce the rupture of tumor blood vessel wall 
and cancer cell membrane. This may enhance delivery of the drugs into cancer cells. Cavitation threshold, 
defined as minimal ultrasound pressure producing cavitation, is dependent on the size of the nanoparticle. 
Hence, the ability to synthesize glyconanoparticles in different sizes with different carbohydrate monomer 
contents may be useful to provide nano-polymeric tools for these applications.  
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CHAPTER V 
 
MATERIALS AND METHODS 
 
  
5.1 Synthetic Procedures 
 
 All chemicals required for the synthesis of carbohydrate compounds were purchased from one of the 
following sources: Sigma Aldrich, Fisher Scientific, Across Organics, TCI Organic Chemicals, or Lancaster 
Research Chemicals. Most were used without further purification. Solvents were obtained from Fisher 
Scientific. Products were purified by flash chromatography using J. T. Baker chromatography silica gels (40 
µm). NMR spectra were recorded in either CDCl3 or D2O as indicated. 
 
5.1.1 Preparation of O-isopropylidene protected carbohydrate acrylates 
 
1,2:5,6-Di-O-isopropylidine-α-D-glucofuranoside (6): Anhydrous D-glucose (10g) was stirred vigorously 
with 200 mL of acetone in an ice bath. Conc. H2SO4 (8 mL) was added in 1 mL portions at 10-15 min intervals, 
while maintaining the temperature at 5-10 oC. After the addition of the sulfuric acid, the vigorous stirring was 
continued for 5h, allowing the temperature to rise gradually to 20-25 oC. The solution was cooled again (ice 
bath), and 50% sodium hydroxide solution (12.25g of NaOH in 15 mL of water) was added with stirring to near 
neutrality. A small amount of sodium hydrogen carbonate was added to maintain the solution near neutrality. 
After standing overnight, the salts were removed by filtration, and the acetone solution was concentrated under 
reduced pressure to a thick syrup that solidifies on standing. The mixture was dissolved in chloroform in a water 
bath, and the solution was extracted with water to remove the mono-O-isopropylidene derivative. The 
chloroform solution was concentrated under reduced pressure to provide a syrup and compound 5 was obtained 
after recrystallization from cyclohexane (11.8 g, 82%) as a white solid; mp 108-110 oC; 1H NMR (250MHz, 
CDCl3): δ 5.95 (d, 1H, J =3.6 Hz), 4.54 (d, 1H, J =3.6 Hz), 4.32 (m, 2H), 4.17 (m, 1H), 3.97 (m, 2H), 1.49 (s, 
3H), 1.44 (s, 3H), 1.37 (s, 3H), 1.35 (s, 3H). 
 
1,2:5,6-Di-O-isopropylidine-α-D-glucofuranose-3-acrylate (1): To a stirred solution of 1,2:5,6-Di-O-
isopropylidine-α-D-glucofuranoside (6) (2.0g, 7.69 mmol) and triethylamine (1.6 mL, 11.53 mmol) in CH2Cl2 
(10 mL) acryloyl chloride (0.68 mL, 8.46 mmol) was added dropwise at 0 oC and  and stirred at room 
temperature for 10 h. The reaction mixture was treated with water (25 mL) and extracted into CH2Cl2 (3X50 
mL). The combined organic layers were washed with water (2X100 mL), dried (Na2SO4) and evaporated under 
reduced pressure. The residue was purified by column chromatography (hexane-EtOAc, 8.5:1.5) to afford the 
compound (1.6 g, 68%) as a white solid; mp 66-68 oC; 1H NMR (250 MHz, CDCl3): δ 6.45 (d, 1H, J =17.1 Hz), 
6.10 (dd, 1H, J =10.3, 17.2 Hz), 5.88 (m, 2H), 5.28 (m, 1H), 4.50 (d, 1H, J =3.7 Hz), 4.20 (m, 2H), 4.01 (m, 
2H), 1.48 (s, 3H), 1.36 (s, 3H), 1.26 (s, 6H); 13C NMR (63 MHz, CDCl3): δ 164.6, 123.0, 127.6, 112.2, 109.2, 
104.9, 83.1, 79.6, 76.1, 72.3, 67.0, 26.7, 26.6, 26.1, 25.1. 
 
1,2:3,4-Di-O-isopropylidine-α-D-galactopyranoside (7): 9g (0.05 mol) of finely powdered anhydrous D-
galactose, 20g (0.125 mol) of anhydrous CuSO4, 1 mL of conc. H2SO4 and 200 mL of anhydrous acetone were 
mixed together and was stirred 24 hrs. CuSO4 was removed by filtration and washed with anhydrous acetone. 
The washings and filtrate were neutralized by shaking with 9.4g (0.127 mol) of calcium hydroxide, and calcium 
sulfate was filtered off and washed with dry acetone. Solvents were removed under reduced  pressure to afford 
the compound 7( 9.63 g, 74%) as a syrup.1H NMR (250MHz, CDCl3): δ 5.5 (d, 1H, J =5.0 Hz), 4.53 (dd, 1H, J 
=2.2, 7.9 Hz), 4.25(m, 2H), 3.83(m, 1H), 3.66(m, 2H), 2.92(m, 1H), 1.46(s, 3H), 1.38(s, 3H), 1.26(s, 6H). 
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1,2:3,4-Di-O-isopropylidine-α-D-galactopyranose-6-acrylate (2): To a stirred solution of 1,2:5,6-di-O- 
isopropylidine-α-D-galactopyranoside (7) (2.0g, 7.69 mmol) and triethylamine (1.6 mL, 11.53 mmol) in CH2Cl2 
(10 mL) acryloyl chloride (0.68 mL, 8.46 mmol) was added dropwise at 0 oC and  stirred at room temperature 
for 10 h. The reaction mixture was treated with water (25 mL) and extracted into CH2Cl2 (3X50 mL). The 
combined organic layers were washed with water (2X100 mL), dried (Na2SO4) and evaporated under reduced 
pressure to afford compound 2 (1.52 g, 65%) as a syrup. 1H NMR (250 MHz, CDCl3): δ 6.44 (d, 1H, J =17.1 
Hz), 6.11 (dd, 1H, J =9.3, 17.0 Hz), 5.83 (d, 1H, J =9.7 Hz), 5.52 (s, 1H), 4.61 (m, 1H), 4.31 (m, 4H), 4.05 (m, 
1H), 1.48 (s, 3H), 1.43 (s, 3H), 1.31 (s, 6H); 13C NMR (63 MHz, CDCl3): δ 166.0, 131.1, 128.1, 109.5, 108.7, 
96.2, 70.9, 70.5, 70.3, 65.9, 63.4, 25.9, 24.9, 24.4. 
 
2,3:5,6-Di-O-isopropylidine-α-D-mannofuranoside (8): D-Mannose (10 g, 55.5 mmol) was suspended in 20 
mL of anhydrous acetone to which was added in rapid succession fused ZnCl2 (12 g, 88.04 mmol) and a 
homogeneous mixture of P2O5 (2 g, 14.09 mmol) and 85%H3PO4 (4 g, 34.6 mmol). The mixture was stirred for 
2 hrs until solution was complete and allowed to stand overnight at room temperature. The mixture was then 
made alkaline by adding an aqueous suspension of Na2CO3 and the precipitate of Zn2CO3 was filtered, washed 
with acetone, and the combined filtrate and washings were distilled in vacuo until most of the acetone was 
removed. The residue was purified by column chromatography (silica gel, hexane-EtOAc, 1:1) to afford the 
compound 8 (12.2 g, 85%) as a syrup.1H NMR (250 MHz, CDCl3): δ 5.38 (d, 1H, J =2.1 Hz), 4.82 (m, 1H), δ 
4.63 (d, 1H, J =5.8 Hz), 4.37(m, 1H), 4.20(m, 1H), 3.04(m, 2H), 1.45(s, 6H), 1.37(s, 3H), 1.32(s, 3H).  
 
2,3:5,6-Di-O-isopropylidine-α-D-mannofuranose-1-acrylate (3): To a stirred solution of 1,2:5,6-di-O-
isopropylidine-α-D-mannofuranoside (8) (2.0g, 7.69 mmol) and triethylamine (1.6 mL, 11.53 mmol) in CH2Cl2 
(10 mL) acryloyl chloride (0.68 mL, 8.46 mmol) was added dropwise at 0 oC and  stirred at room temperature 
for 10 h. The reaction mixture was treated with water (25 mL) and extracted into CH2Cl2 (3X50 mL). The 
combined organic layers were washed with water (2X100 mL), dried (Na2SO4) and evaporated under reduced 
pressure. The residue was purified by column chromatography (hexane-EtOAc, 8.5:1.5) to afford the compound 
3(1.44 g, 62%)  as a syrup .1H NMR (250 MHz, CDCl3): δ 6.45 (d, 1H, J =18.3 Hz), 6.17 (s, 1H), 6.07 (dd, 1H, 
J =10.3, 17.1 Hz), 5.89 (d, 1H, J =10.4 Hz), 4.85 (m, 1H), 4.73 (m, 1H), 4.37 (m, 1H), 4.02 (m, 3H), 1.46 (s, 
3H), 1.43 (s, 3H), 1.34 (s, 3H), 1.31 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 164.3, 132.2, 127.7, 113.2, 109.3, 
100.9, 85.0, 82.2, 79.2, 72.8, 66.7, 26.9, 25.8, 25.0, 24.5. 
 
Methyl 2,3-isopropylidine-β-D-ribofuranoside (9): A solution  of dry D-ribose (5.0 g, 33.30 mmol)  in 100 
mL of acetone, 2,2-dimethoxypropane (10 mL, 68.5 mmol), and 20 mL of methanol containing 2mL methanol 
saturated with hydrogen chloride at 0 oC was stirred at 25 overnight. The resulting solution was neutralized with 
pyridine and evaporated to a yellow oil. This oil was partitioned between 50 mL of water and 20 mL of ether. 
The water layer was extracted twice with 20 mL portions of ether, and the combined ether extracts were dried 
over MgSO4. Evaporation yielded a pale yellow oil which was purified by column chromatography (hexane-
EtOAc,2:1 ) to afford  compound 9 (4.7g,  86%) as an oil. 1H NMR (250 MHz, CDCl3): δ 4.91 (s, 1H), 4.78 (d, 
1H, J=5.8 Hz), 4.54 (d, 1H, J=5.8 Hz), 4.35 (s, 1H), 3.58 (m, 2H), 3.37 (s, 3H), 3.17 (s, 1H), 1.42 (s, 3H),  1.26 
(s, 3H).  
 
Methyl 2,3-isopropylidine-β-D-ribofuranose-5-acrylate (4): To a solution of methyl 2,3-isopropylidene-β-D-
ribofuranoside (9) (1.0 g, 4.9 mmol) in CH2Cl2 (5 mL) with triethylamine (1.0 mL, 7.3 mmol), acryloyl chloride 
(0.43 mL, 5.4 mmol) was added dropwise at 0 oC. The mixture was magnetically stirred for 30 min. at 0 oC and 
then for another 8 hrs at room temperature. The reaction mixture was treated with water (15 mL) and extracted 
into CH2Cl2 (3 x 25 mL). The combined organic layers were washed with water (2 x 50 mL), dried over 
anhydrous MgSO4 and evaporated under reduced pressure. The residue was purified by column chromatography 
(silica gel, hexane-EtOAc, 8.5:1.5) to afford the compound 4 (1.04 g, 83%) as a syrup. 1H NMR (250 MHz, 
CDCl3): δ 6.42 (d, 1H, J =16.3 Hz, olefinic), 6.10 (dd, 1H, J =10.3, 17.3 Hz, olefinic), 5.82 (d, 1H, J =10.3 Hz, 
olefinic), 4.92 (s, 1H, H-1), 4.63 (d, 1H, J =5.9 Hz, H-3), 4.55 (d, 1H,  J =5.9 Hz, H-2), 4.35 (t, 1H, J=6.9 Hz, 
H-4), 4.11 (m, 2H, H-5,5’), 3.25 (s, 3H, OCH3), 1.42 (s, 3H, CH3), 1.26 (s, 3H, CH3); 13C NMR (63 MHz, 
CDCl3): δ 165.5, 131.3, 127.9, 112.4, 109.2, 85.0, 84.0, 81.7, 64.5, 54.7, 26.3, 24.8. 
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5.1.2 Preparation of O-acetal-protected acrylamide from glucosamine 
 
1,3,4,6-Tetra-O-acetyl-β-D-glucosamine hydrochloride (12): To a solution of D-glucosamine hydrochloride 
(2.5 g, 11.6 mmol) in a freshly prepared aqueous solution of 1M NaOH (12 mL) under stirring was added p-
anisaldehyde (1.7 mL, 12.36 mmol). Then the mixture was refrigerated and after 2 h the precipitated product 
was filtered off and washed with cold water, and followed by a mixture of 1:1 EtOH-Et2O to give 2-deoxy-2-[p-
methoxybenzylidene(amino)]-D-glucopyranose (10). This intermediate product (2.5g) was added successively 
to a cooled (ice-water) mixture of pyridine (13.5 mL) and Ac2O (7.5 mL). The mixture was stirred in ice bath ~ 
1 h and then at room temperature overnight. The yellow solution was poured into 50 mL of ice-water. The 
precipitated white product was filtered, washed with cold water and dried. Subsequently this product, 1,3,4,6-
tetra-O-acetyl-2-deoxy-2-[p-methoxybenzylidene(amino)]-D-glucopyranose (11) (3.4 g),was dissolved in warm 
acetone (30 mL), and then HCl (5M, 1.5 mL) was added with immediate formation of a precipitate. The mixture 
was cooled, and after addition of Et2O (30 mL), it was stirred for 2 hrs and refrigerated overnight. The 
precipitated product was filtered, washed with Et2O and dried to give compound 12 (1.56 g, 56%) as a white 
solid; mp 234-236 oC; 1H NMR (250 MHz, D2O): δ 5.86 (m, 1H), 5.36 (m, 1H), 5.03 (m, 1H), 4.26 (m, 1H), 
4.11 (m, 2H), 3.63 (m, 1H), 2.01 (m, 12H). 
 
N-Acryloyl 1,3,4,6-tetra-O-acetyl-β-D-glucosamine (5): To a suspension of 1,3,4,6-tetra-O-acetyl-β-D-
glucosamine hydrochloride (12) (1.0g, 2.6 mmol) and triethylamine (0.54 mL, 3.9  mmol)  in CH2Cl2 (10 mL) 
acryloyl chloride (0.23 mL, 2.86 mmol) was added dropwise at 0 oC and  stired at room temperature for 10 h. 
The reaction mixture was treated with water (25 mL) and extracted into CH2Cl2 (3X50 mL). The combined 
organic layers washed with water (2X50 mL), dried (Na2SO4) and evaporated under reduced pressure. The 
residue was purified by column chromatography (hexane-EtOAc, 2:1) to afford the compound (0.67 g, 65%) as 
a white solid; mp 180 oC; 1H NMR (250 MHz, CDCl3): δ 6.28 (d, 1H, J =16.3 Hz), 5.99 (dd, 1H, J =10.8, 16.6 
Hz), 5.70 (m, 3H), 5.18 (m, 2H), 4.42 (m, 1H), 4.31 (m, 1H), 4.15 (m, 1H), 3.81 (m, 1H) 2.09 (s, 3H), 2.04 (s, 
3H), 2.01 (s, 3H), 1.6 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 171.4, 170.7, 169.6, 169.3, 165.4, 130.1, 127.6, 
92.6, 72.9, 72.6, 67.8, 61.7, 52.8, 20.9, 20.7, 20.6. 
 
5.1.3 Preparation of carbohydrate acrylate monomers with bulky aryl protecting groups  
 
Methyl 2,3,5-tri-O-benzyl-β-D-ribofuranoside (15): A solution of D-ribose (2.5g, 16.65 mmol) in 50 mL of 
anhydrous methanol was cooled to 0 oC and treated with 0.25 mL of conc. H2SO4. After storage in the freezer 
overnight, the solution was neutralized by adding Na2CO3 then filtered, and the product, methyl β-D-
ribofuranoside, was isolated by evaporating the solvent. This intermediate product (2.6g, 15.8 mmol) was 
dissolved in 25 mL of dry DMF and stirred with NaH (4.4g, 110.6 mmol, 60% dispersion in mineral oil ) for 2 h 
at room temperature. The mixture was cooled to 0 oC and benzyl bromide (18.1 mL, 79 mmol) was added 
dropwise to the mixture and stirring was continued overnight at room temperature. The mixture was cooled to 0 
oC and excess NaH was decomposed by dropwise addition of MeOH (5 mL). The solution was concentrated in 
vacuo and diluted with EtOAc (125 mL) and water ( 65 mL). The organic phase was separated, washed with 
water (3X 30 mL) and brine (30 mL). The solvents were evaporated and the residue was purified by column 
chromatography (hexane-EtOAc, 9:1) to give compound 15 (2.6 g,  62 %) as a colorless syrup; 1H NMR (250 
MHz, CDCl3): δ 7.33 (m, 15H), 4.95 (s, 1H), 4.59 (m, 6H), 4.34 (m, 1H), 4.07 (m, 1H), 3.88 (m, 1H), 3.61 (m, 
2H), 3.34 (s, 3H). 
 
2,3,5-Tri-O-benzyl-β-D-ribofuranose (16): Methyl 2,3,5-tri-O-benzyl-β-D-ribofuranoside (15) (2.5g, 9.9 
mmol) was dissolved in 50 mL of dioxane and 12.5 mL of 0.1N HCl was added and boiled gently till 12.5 mL 
of distillate was collected. After cooling, it was made up to its original volume by adding 12.5 mL of a mixture 
of 12 parts of water and 88 parts of dioxane (v./v.). More 0.1N HCl (12.5) mL was added and the process was 
repeated and 10 mL of the distillate was removed. The remaining solution was neutralized with 1N NaOH, the 
solution was concentrated in vacuo. The residual syrup was dissolved in CH2Cl2, washed with water (3X20 mL) 
and dried over anhydrous MgSO4. The crude product was purified by column chromatography to give the 
compound 16 (1.91g, 81 %) as a syrup; 1H NMR (250 MHz, CDCl3): δ 7.28 (m, 15H), 5.35 (s, 1H), 4.58 (m, br, 
7H), 3.99 (m, 2H), 3.48 (m, 2H). 
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2,3,5-Tri-O-benzyl-β-D-ribofuranose-1-acrylate(13): To a solution of 2,3,5-tri-O-benzyl-β-D-ribofuranose 
(16) (1.0 g, 4.19 mmol) in CH2Cl2 (5 mL) with triethylamine ( 0.87 mL, 6.28mmol),  acryloyl chloride (0.37 
mL, 4.6 mmol) was added dropwise at 0 oC. The mixture was magnetically stirred for 30 min. at 0 oC and then 
for another 8 hrs at room temperature. The reaction mixture was treated with water (15 mL) and extracted into 
CH2Cl2 (3 x 25 mL). The combined organic layers were washed with water (2 x 50 mL), dried over anhydrous 
MgSO4 and evaporated under reduced pressure. The residue was purified by column chromatography (silica gel, 
hexane-EtOAc, 3:1) to afford the compound 13 (1.04 g, 83%) as a syrup. 1H NMR (250 MHz, CDCl3): δ 7.35 
(m, 15H), 6.31 (m, 2H), 6.02 (m, 1H), 5.81 (m, 1H), 4.84 (m, 1H), 4.69 (m, br, 6H), 4.42 (m, 1H), 4.01 (m, 1H), 
3.65 (m, 2H); 13C NMR (63 MHz, CDCl3): δ 164.6, 138.2, 137.5, 137.3, 131.8, 128.4, 128.2, 128.1, 127.9, 
127.8, 127.5, 99.3, 81.6, 78.7, 77.6, 77.0, 76.8, 76.5, 73.2, 72.4, 72.0, 69.5. 
 
N-Acryloyl-1,3,4,6-tetra-O-benzoyl-β-D-glucosamine (14): 2-Deoxy-2-[p-methoxybenzylidene (amino)]-D-
glucopyranose (10) (0.5 g, 1.68 mmol) was added successively to a cooled (ice-water) mixture of pyridine (10 
mL) and stirred. Benzoyl chloride (3.2 mL, 27.77 mmol) was added dropwise and stirred at room temperature 
for 5h. The mixture was washed with saturated NaHCO3 and extracted with Et2O, and washed with water. 
Solvents were evaporated in vacuo and the residue was dissolved in acetone (30 mL), and then HCl (5M, 2 mL) 
was added with immediate formation of a precipitate. The mixture was cooled, and after addition of Et2O (30 
mL), was stirred for 2 hrs at 0 oC. The precipitated product was filtered, washed with Et2O and dried to give 
1,3,4,6-tetra-O-benzoyl-β-D-glucosamine hydrochloride (18).To a suspension of compound 18 (0.5g, 0.79 
mmol) and triethylamine (0.16 mL, 1.18mmol)  in CH2Cl2 (10 mL) acryloyl chloride (0.07 mL, 2.86 0.87mmol) 
was added dropwise at 0 oC and  stired at room temperature for 10 h. The reaction mixture was treated with 
water (25 mL) and extracted into CH2Cl2 (3X50 mL). The combined organic layers washed with water (2X50 
mL), dried (Na2SO4) and evaporated under reduced pressure. The residue was purified by column 
chromatography (hexane-EtOAc, 2:1) to afford compound 14 (0.44 g, 40%) as a syrup.1H NMR (250 MHz, 
CDCl3): δ 7.95 (m, 8H), 7.36 (m, 12H), 5.90 (m, 5H), 5.46 (m, 1H), 4.60 (m, 1H), 4.51 (m, 2H), 4.28 (m, 1H). 
 
5.1.4 Deacetonation of carbohydrate acrylates  
 
3-Acryloyl-D-glucose (19): 1,2:5,6-Di-O-isopropylidine-α-D-glucofuranose-3-acrylate (1) (0.5 g, 1.59 mmol)  
was dissolved in 1 mL of 90% trifluoroacetic acid, stirred 30 min. at room temperature, and the solvents were 
removed in vacuo to afford compound 19 (0.33 g, 90%) as a syrup. 1H NMR (400MHz, D2O): δ 6.30 (dd, 1H, J 
2.4, 17.2 Hz), 6.08 (dd, 1H, J =10.8,17.6 Hz), 5.84(dd, 1H, J =3.2,10.4 Hz), 5.04(m, 1H), 4.87(m, 1H), 3.77-
3.26(m, 5H);13C NMR (63 MHz, D2O): δ 168.2, 168.0, 133.0, 132.8, 127.3, 127.2, 95.7, 91.9, 77.5, 75.6, 75.4, 
72.3, 71.1, 69.7, 67.7, 60.4, 60.3.    
 
Methyl β-D-ribofuranose-5-acrylate (20): Methyl 2,3-O-isopropylidene-β-D-ribofuranose-5-acrylate (5) (0.50 
g, 1.9 mmol) was dissolved in 80% acetic acid and stirred at 80 oC for 2 h. The solvent was then removed in 
vacuo and the residue was purified by column chromatography (silica gel, hexane-EtOAc, 1:6) to give 
compound 20 (0.28 g, 68%) as a syrup. 1H NMR (400 MHz, CDCl3): δ 6.41 (d, 1H, J =17.6 Hz, olefinic), 6.12 
(dd, 1H, J =10.4,17.2 Hz, olefinic), 5.83 (d, 1H, J =10.8 Hz, olefinic), 4.79 (s, 1H, H-1), 4.40 (m, 1H), 4.15 (m, 
3H), 3.97 (d, 1H, J=4.4 Hz), 3.59 (s, br, 2H, OH), 3.28 (s, 3H, OCH3);13C NMR (100 MHz, CDCl3): δ 166.1, 
131.8, 128.2, 108.3, 80.9, 75.1, 72.1, 65.3, 55.2.   
 
5.1.5 Preparation of nucleoside acrylates  
 
2’, 3’-O-Isoprpylidene cylidine (21):   Cytidine (1 g, 4.11 mmol) and p-toluenesulfonic acid monohydrate 
(7.85 g, 41.26 mmol) were suspended in 150 ml of acetone and stirred for 2 hrs at room temperature. The 
precipitate formed was separated by filtration. This was dissolved in aq. NaHCO3 (1.2 eq) and stirred for an 
hour. The solvents were evaporated and the residue was extracted with CHCl3.  Compound 21 (0.83 g,  72%) 
was obtained after removing solvents as a syrup. 1H NMR (250 MHz, CDCl3): δ 8.95 (s, 2H), 7.79 (d, 1H, J=7.4 
Hz), 7.48 (d, 1H, J=7.4 Hz),  5.55 (d, 1H, J=2.5 Hz), 5.25 (dd, 1H, J=2.6, 6.5 Hz), 5.09 (dd, 1H, J=3.1, 6.5 Hz), 
4.41 (d, 1H, J=2.5, Hz), 3.95 (m, 1H), 3.88 (m, 1H), 3.86 (m, 1H), 3.85 (m, 1H), 3.60 (m, 1H), 1.61 (s, 3H), 
1.38 (s, 3H). 
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4-N-Acetyl-2’,3’-O-isopropylidene cytidine (22):  2’, 3’-O-Isoprpylidene cylidine (21) (0.5g, 1.76 mmol ) was 
dissolved in 50 mL of anhydrous methanol and 0.5 mL of Ac2O was added and heated to reflux. Three portions 
of 0.5 mL Ac2O were added to the refluxing mixture at every 45 minutes and refluxed another hour. The 
solvents were evaporated under reduced pressure and the residue was washed with ether. The residue was 
purified by column chromatography to afford compound 22 (0.46g,   81 %) as a white solid; mp 115-117 oC; 1H 
NMR (250 MHz, CDCl3): δ 7.34 (d, 1H, J=7.4), 5.78 (d, 1H, J=7.2), 5.41 (s, 1H), 5.03 (m, 1H), 4.90 (m, 1H), 
4.19 (d, 1H, J=2.5), 3.82 (m, 2H), 2.30 (s, 3H), 1.46 (s, 3H), 1.25 (s, 3H). 
 
4-N-Acetyl-5’-O-acryloyl-2’,3’-O-isopropylidene cytidine (23): To a stirred solution of 4-N-acetyl-5’-O-
acryloyl-2’,3’-O-isopropylidene cytidine (22) (0.25g, 0.77 mmol) and triethylamine (0.16 mL, 1.15mmol) in 
CH2Cl2 (5 mL) acryloyl chloride (0.068 mL, 0.85mmol) was added dropwise at 0 oC and  stirred at room 
temperature for 10 h. The reaction mixture was treated with water (15 mL) and extracted into CH2Cl2 (3X25 
mL). The combined organic layers were washed with water (2X50 mL), dried (Na2SO4) and evaporated under 
reduced pressure. The residue was purified by column chromatography to afford  compound 23 (0.17 g, 60%) as 
a white solid; mp 109 oC; 1H NMR (400MHz, CDCl3): δ 7.71(d, 1H, J=7.6 Hz), 7.39(d, 1H, J=7.2 Hz), 6.40(d, 
1H, J=17.2 Hz), 6.02(dd, 1H, J =10.4, 17.2 Hz), 5.84(d, 1H, J=10.8 Hz), 5.68(s, 1H), 5.01(d, 1H, J=6.0 Hz), 
4.84(m, 1H), 4.43(m, 3H), 2.93(s, 3H), 1.55(s, 3H), 1.33(s, 3H);13C NMR (63 MHz, CDCl3): δ 165.5, 163.2, 
154.6, 146.3, 131.8, 127.6, 114.2, 96.8, 96.5, 86.4, 85.2, 81.3, 64.4, 27.1, 25.2, 24.9. 
 
5.1.6 Preparation of carbohydrate-based acrylated acyl chlorides 
 
3-O-Acryloyl-1,2-O-isopropylidene-α-D-glucofuranoside(29):1,2:5,6-Di-O-isopropylidine-α-D-glucofurano- 
-se-3-acrylate (1) (0.5g, 1.59 mmol) was dissolved in 4 mL of 80% acetic acid and  stirred 4hrs at room 80 oC. 
The solvents were removed in vacuo and the residue was purified by column chromatography (silica gel, 
hexane-EtOAc, 1:1) to afford compound 29 (0.32 g, 62%) as a syrup. 1H NMR (400 MHz, D2O): δ 6.32 (d, 1H, 
J =20.0 Hz), 6.02 (m, 1H), 5.86 (m, 2H), 5.16 (m, 1H), 4.12 (m, 1H), 3.73 (m, 1H), 3.59 (m, 1H), 3.45 (m,1H), 
1.36 (s, 3H), 1.17(s, 3H);13C NMR (63 MHz, D2O): δ 166.8, 133.3, 126.8, 113.0, 104.7, 82.2, 78.3, 75.9, 67.9, 
63.1, 25.3, 25.0. 
 
3-O-Acryloyl-1,2-O-isopropylidene-5,6 bis(carboxypropanoyl)-α-D-glucofuranose (30): 3-O-Acryloyl-1,2-
O-isopropylidene-α-D-glucofuranoside (29) (0.3g, 1.09 mmol) and succinic anhydride (0.65g, 6.54 mmol) were 
stirred with Et3N (0.76 mL, 5.45 mmol) in CH2Cl2 (10 mL) at rt for 5h. The reaction mixture was washed with 
5% KHSO4, then water. The organic layer was dried over Na2SO4, filtered and evaporated to dryness. The 
brown oil obtained was chromatographed on silica gel (EtOAc) and the solid obtained was centrifuged in 
CH2Cl2. After evaporation of the solvent, compound 30 (0.34g, 65%) was obtained as a syrup. 1H NMR (400 
MHz, CDCl3): δ 9.18 (br, s, 2H), 6.34 (m, 1H), 6.01 (m, 1H), 5.81 (m, 2H), 5.27 (m, 2H), 4.57(m, 3H), 4.13(m, 
1H), 2.57(m, 8H), 1.46(s, 3H), 1.26(s, 3H);13C NMR (400 MHz, CDCl3): δ 177.8, 177.6, 172.0, 171.0, 164.9, 
132.8, 127.3, 112.8, 105.3, 83.3, 76.8, 75.3, 68.1, 63.6, 29.0, 28.9, 28.8, 26.8, 26.4. 
 
3-O-Acryloyl-1,2-O-isopropylidene-5,6 bis((chlorosuccinyl)oxy)-α-D-glucofuranose (27): Compound 30 
(0.3g, 0.80 mmol ) was dissolved in 3 mL of thionyl chloride, stirred 45 min. at room temperature, and the 
solvents were removed in vacuo to afford compound 27 (0.31g, 98%) as a syrup. 1H NMR (400 MHz, CDCl3): 
δ 6.39 (m, 1H), 6.04 (m, 1H), 5.87 (m, 2H), 5.28 (m, 2H), 4.50 (m, 3H), 4.17 (m, 1H), 3.13 (m, 4H), 2.62 (m, 
4H) 1.48 (s, 3H), 1.27 (s, 3H);13C NMR (100 MHz, CDCl3): δ 173.2, 172.9, 171.0, 170.1, 169.8, 165.7, 164.7, 
132.5, 127.5, 112.8, 105.3, 83.3, 76.6, 75.2, 68.5, 63.8, 41.8, 29.3, 28.6, 26.9. 
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6-O-Acetyl-3-O-acryloyl-1,2-O-isopropylidene-α-D-glucofuranoside(31): 3-O-Acryloyl-1,2-O-isopropylid- 
-ene-α-D-glucofuranoside (29) (0.4 g, 1.52 mmol) was dissolved in 10 mL of CH2Cl2 and cooled to -40 oC. 
Collidine (0.36 g, 3.04 mmol) was added to the solution and acetyl chloride was added and stirred at -40 oC for 
3 h and at rt for 1 h. The mixture was washed with water and extracted into CH2Cl2 (3X25 mL). The solvents 
were evaporated and the residue was purified by column chromatography to afford  compound 31 (0.33 g, 72 
%) as a syrup. 1H NMR (400 MHz, CDCl3): δ 6.70 (s, 1H), 6.42 (d, 1H, J=17.2 Hz), 6.06 (dd, 1H, J =10.4, 17.2 
Hz), 5.84 (m, 2H), 5.32 (m, 2H), 4.52 (m, 1H), 4.36 (m, 1H), 4.20 (m, 1H), 4.09 (m, 1H), 3.85 (m, 1H), 2.00 (s, 
3H), 1.45 (s, 3H), 1.25 (s, 3H);13C NMR (100 MHz, CDCl3): δ 171.4, 165.8, 157.3, 147.8, 132.9, 127.4, 121.4, 
112.5, 105.1, 79.0, 76.6, 66.6, 24.1, 20.9. 
 
6-O-Acetyl-3-O-acryloyl-1,2-O-isopropylidene-5-carboxypropanoyl-α-D-glucofuranose (32): 6-O-Acetyl-
3-O-acryloyl-1,2-O-isopropylidene-α-D-glucofuranoside (31) (0.3 g, 0.98 mmol) and succinic anhydride (0.29 
g, 2.96 mmol) were stirred with Et3N (0.34 mL, 2.45mmol) in CH2Cl2 (10 mL) at rt for 5h. The reaction mixture 
was washed with 5% KHSO4, then water. The organic layer was dried over Na2SO4, filtered and evaporated to 
dryness. The brown oil obtained was chromatographed on silica gel (EtOAc) and the solid obtained was 
centrifuged in CH2Cl2. After evaporation of the solvent, compound 32 (0.26 g, 65%) was obtained as a syrup. 
1H NMR (400 MHz, CDCl3): δ 9.17 (br, s, 1H), 6.37 (d, 1H, J=17.2 Hz), 6.06 (dd, 1H, J =10.4, 17.2 Hz), 
5.88(m, 2H), 5.34(d, 1H, J=2.8 Hz), 5.23(m, 1H), 4.51(m, 3H), 4.12(dd, 1H, J =5.6, 12.4 Hz), 2.55(m, 4H), 
2.02(s, 3H), 1.51(s, 3H), 1.30(s, 3H);13C NMR (100 MHz, CDCl3): δ 177.3, 171.3, 171.2, 165.1, 132.9, 127.6, 
113.0, 105.5, 83.6, 77.2, 77.1, 75.6, 68.4, 63.7, 29.3, 27.2, 26.7, 21.1. 
 
6-O-Acetyl-3-O-acryloyl-1,2-O-isopropylidene-5-(chlorosuccinyl)oxy-α-D-glucofuranose (28): 0.3 g of 32 
was dissolved in 3 mL of thionyl chloride, stirred 45 min. at room temperature, and the solvents were removed 
in vacuo to afford compound 28 (0.34 g, 98%) as a syrup. 1H NMR (400 MHz, CDCl3): δ 6.35 (d, 1H, J=17.2 
Hz), 6.04 (dd, 1H, J =10.4, 17.2 Hz), 5.87 (m, 2H), 5.33 (d, 1H, J=2.8 Hz), 5.17 (m, 1H), 4.52 (m, 3H), 4.08 
(dd, 1H, J =5.6, 12.4 Hz), 3.10 (m, 3H), 2.57 (m, 3H), 2.00 (s, 3H), 1.49 (s, 3H), 1.27 (s, 3H);13C NMR (100 
MHz, CDCl3): δ 172.8, 170.8, 169.8, 164.8, 132.7, 127.3, 112.7, 105.3, 83.3, 76.8, 75.2, 68.6, 63.2, 41.7, 29.4, 
28.6, 26.3, 20.8. 
 
5.1.7 Preparation of antibiotic-conjugated carbohydrate monomers 
 
Monomer 34: To a stirred solution of N-sec-butylthio β-lactam derivative 33 (0.2 g, 0.7 mmol) and 
triethylamine (0.29 mL, 2.1 mmol) in CH2Cl2 (5 mL) diacyl chloride 27 (0.173g, 0.42 mmol in 0.5 mL of 
CH2Cl2) was added dropwise at 0 oC and stirred at room temperature for 10 h. The reaction mixture was treated 
with water (10 mL) and extracted into CH2Cl2 (3X15 mL). The combined organic layers were washed with 
water (2X50 mL), dried (MgSO4) and evaporated under reduced pressure.  The residue was purified by column 
chromatography (hexane-EtOAc, 2:1) to afford the compound 34 (0.22 g, 62%) as a syrup.  1H NMR (400 
MHz, CDCl3): δ 7.35 (m, 8H), 6.35 (d, 1H, J=17.2 Hz), 6.14 (m, 2H), 6.03 (dd, 1H, J =10.8, 17.6 Hz), 5.84 (m, 
2H), 5.47 (m, 2H), 5.25 (s, 1H), 5.09 (m, 1H), 4.45 (m, 2H), 4.33 (m, 1H), 4.05 (m, 1H), 3.04 (m, 2H), 2.17 (m, 
8H), 1.56 (m, 4H), 1.47 (s, 3H), 1.26 (m, 9H), 0.96 (m, 6H);13C NMR (100 MHz, CDCl3): δ 171.2, 170.3, 
169.8, 169.0, 164.7, 134.6, 123.6, 130.7, 130.1, 130.0, 128.9, 127.3, 126.9, 112.7, 105.3, 83.3, 75.3, 68.0, 63.7, 
63.6, 48.6, 28.5, 28.3, 26.9, 26.4, 19.2, 18.9, 11.3. 
 
Monomer 36: To a stirred solution of ciprofloxacin hydrochloride (35) (0.2g, 0.6 mmol) and triethylamine (0.5 
mL, 3.6 mmol) in CH2Cl2 (8 mL) diacyl chloride 27 (0.148 g, 0.36 mmol in 0.5 mL of CH2Cl2) was added 
dropwise at 0 oC and stirred at room temperature for 10 h. The reaction mixture was treated with water (10 mL) 
and extracted into CH2Cl2 (3X15 mL). The combined organic layers were washed with water (2X50 mL), dried 
(MgSO4) and evaporated under reduced pressure.  The residue was purified by column chromatography 
(EtOAc) to afford compound 36 (0.16 g, 50%) as a yellow solid; mp > 80 oC (decomposition);1H NMR (250 
MHz, CDCl3): δ 14.87(br, s, 2H), 8.55(s, 2H), 7.78 (d, 2H, J=12.8 Hz), 7.32 (d, 2H, J=6.8 Hz), 6.43 (d, 1H, 
J=17.2 Hz), 6.14 (dd, 1H, J =10.3, 16.9 Hz), 5.91 (m, 2H), 5.35 (m, 2H), 4.54 (m, 3H), 4.21(m, 1H), 3.81(s, 
4H), 3.74(s, 4H), 3.57 (s, 2H), 3.39(s, 4H), 3.30 (s, 4H), 2.70(s, 4H), 2.62(s, 4H), 1.40(s, 3H), 1.38(m, 4H), 
1.30(s, 3H), 1.20(m, 4H). 
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Monomer 37: To a stirred solution of ciprofloxacin hydrochloride (35) (0.2g, 0.6 mmol) and triethylamine (0.5 
mL, 3.6 mmol) in CH2Cl2 (8 mL) acyl chloride 28 (0.31g, 0.66 mmol in 0.5 mL of CH2Cl2) was added dropwise 
at 0 oC and stirred at room temperature for 10 h. The reaction mixture was treated with water (10 mL) and 
extracted into CH2Cl2 (3X15 mL). The combined organic layers were washed with water (2X50 mL), dried 
(MgSO4) and evaporated under reduced pressure.  The residue was purified by column chromatography 
(EtOAc) to afford  compound 37 (0.23 g, 56%) as a syrup. 1H NMR (400 MHz, CDCl3): δ 8.64(s, 1H), 7.90 (d, 
1H, J=12.4 Hz), 7.32 (d, 1H, J=6.8 Hz), 6.39 (d, 1H, J=17.2 Hz), 6.05 (dd, 1H, J =10.4, 17.2 Hz), 5.88 (d, 1H, 
J=3.6 Hz), 5.86 (d, 1H, J=10.4 Hz), 5.32 (d, 1H, J=2.8 Hz), 5.24(m, 1H), 4.52(m, 3H), 4.12 (dd, 1H, J =5.2, 
12.0 Hz), 3.79(m, 2H), 3.68(m, 2H), 3.53(m, 1H), 3.33(m, 2H), 3.25(m, 2H), 2.59(m, 4H), 2.02(s, 3H), 1.49(s, 
3H), 1.37(m, 2H), 1.27(s, 3H), 1.18(m, 2H);13C NMR (100 MHz, CDCl3): δ 177.1, 171.8, 170.8, 169.6, 166.9, 
164.8, 155.0, 152.5, 147.6, 145.6, 145.5, 139.1, 132.3, 127.7, 120.2, 112.7, 112.4, 108.2, 105.3, 105.2, 83.3, 
75.5, 68.0, 63.3, 53.6, 50.2, 49.5, 45.2, 41.5, 35.5, 29.4, 28.1, 26.9, 26.4, 20.9, 8.4. 
 
Monomer 40: 6-Aminopenicillanic acid (2 g, 0.924 mmol) and N, O-bis(trimethylsilyl) acetamide ( 0.21 g, 
1.02 mmol) were  added to CH2Cl2 (10 mL) and stirred at rt overnight. Triethylamine (0.19 mL, 1.38  mmol) 
was added and cooled on ice.  Acyl chloride 28 (0.52 g, 1.11 mmol in 0.5 mL of CH2Cl2) was added dropwise 
and stirred at room temperature for 10 h. The reaction mixture was treated with water (10 mL) and extracted 
into CH2Cl2 (3X15 mL). The combined organic layers were washed with water (2X50 mL), dried (MgSO4) and 
evaporated under reduced pressure.  The residue was purified by column chromatography (EtOAc) to afford 
compound 40 (0.23 g, 56%) as a syrup. 1H NMR (400 MHz, CDCl3): δ 6.55 (d, 1H, J=8.8 Hz), 6.39 (d, 1H, 
J=17.2 Hz), 6.02 (m, 1H), 5.88 (m, 2H), 5.63 (dd, 1H, J =4.0, 8.8 Hz), 5.48 (d, 1H, J=4.0 Hz), 5.31 (m, 1H), 
5.19 (m, 1H), 4.48 (m, 3H), 4.04 (m, 1H), 2.55 (m, 4H), 2.01 (s, 3H), 1.62 (s, 3H), 1.54 (s, 3H), 1.48 (s, 3H), 
1.27 (s, 3H). 
 
5.1.8 Preparation of long-chain acrylated glucose monomers 
 
11-Acryloyloxy undecan-1-ol (44): Sodium hydroxide (13.8 g, 0.345 mol) dissolved in deionized water was 
placed in a round bottomed flask and kept in an ice bath for 10 minutes. Acrylic acid (23.7 mL, 0.345 mol) was 
added dropwise under stirring to the above solution. After 30 minutes, the reaction mixture was freeze-dried. 
The product was then dissolved in methanol and precipitated with diethyl ether. After filtering, sodium acrylate 
(43) (29.2 g, 0.31 mol) was obtained in 90% yield. Sodium acrylate ( 1.65 g, 17.5 mmol), 11-bromoundecan-1-
ol (1.0 g, 4.0 mmol), n-tetrabutylammonium bromide ( 0.375 g, 1.08 mmol), 2,6,-di-t-butyl-4-methyl phenol ( 2 
mg, 0.009 mmol) dissolved in deionized ( 3.5 mL) and chloroform (2 mL) were placed in a round-bottomed 
flask. The reaction vessel was placed in an oil bath at 100 oC, and vigorous magnetic stirring was applied for 
three days. After that time, the chloroform layer was washed with 2% NaOH solution (4X25 mL) and distilled 
water (4X25 mL). The organic layer was dried over magnesium sulfate, and the solvent evaporated and 
compound 44 (0.58 g, 58%) was obtained as a yellowish oil. 1H NMR (250 MHz, CDCl3): δ 6.28 (dd, 1H, J 
=1.6, 17.2 Hz), 5.96 (dd, 1H, J =10.2, 17.2 Hz), 5.82 (dd, 1H, J =1.6, 10.2 Hz), 4.03 (t, 2H, J =6.8), 3.48 (t, 2H, 
J =6.6 Hz), 3.24 (m, 1H), 1.13 (br, s, 18H). 
 
Acrylated acid 45: Compound 44 (0.3 g, 1.24 mmol) and succinic anhydride (0.37 g, 3.74 mmol) were stirred 
with Et3N (0.35 mL, 2.49 mmol) in CH2Cl2 (5 mL) at rt for 5h. The reaction mixture was washed with 5% 
KHSO4, then water. The organic layer was dried over Na2SO4, filtered and evaporated to dryness. The residue 
was purified by column chromatography to afford compound 45 (0.33 g, 80%) as a syrup. 1H NMR (400 MHz, 
CDCl3): δ 6.37 (d, 1H, J=17.2 Hz), 6.08 (dd, 1H, J =10.4, 17.6 Hz), 5.78 (d, 1H, J=10.4 Hz), 4.08 (m, 4H), 2.59 
(m, 4H), 1.59 (m, 4H), 1.23 (m, 14H);13C NMR (63 MHz, CDCl3): δ 177.9, 172.2, 166.4, 130.5, 128.6, 65.0, 
64.7, 29.4, 29.2, 28.9, 28.5, 25.8. 
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Acrylate 46: Acid 45 (0.31 g, 0.90 mmol) was dissolved in CH2Cl2 (5 mL) and EDCI (0.26 g, 1.36 mmol) was 
added and stirred for 10 minutes. Diacetone-D-glucose (0.24, 0.90 mmol) and a catalytic amount of DMAP 
were added and stirred overnight at rt. The solvents were evaporated and the residue was purified by column 
chromatography (hexane-EtOAc, 1:1) to afford the compound 46 (0.39 g, 75%) as a syrup. 1H NMR (400 MHz, 
CDCl3): δ 6.36 (d, 1H, J=17.6 Hz), 6.07 (m, 1H), 5.81 (m, 2H), 5.20 (s, 1H), 4.45 (m, 1H), 4.04 (m, 8H), 2.60 
(m, 4H), 1.59 (m, 4H), 1.46 (s, 3H), 1.35 (s, 3H), 1.25 (m, 20H);13C NMR (63 MHz, CDCl3): δ 172.1, 171.0, 
130.4, 128.6, 112.2, 109.3, 105.0, 83.2, 79.7, 76.3, 72.4, 67.2, 65.0, 64.6, 29.4, 29.2, 29.1, 28.9, 28.6, 26.8, 26.7, 
26.2, 25.8, 25.2. 
 
Monomer 41: Compound 46 (0.3g, 0.51 mmol)  was dissolved in 1 mL of 90% trifluoroacetic acid, stirred 30 
min. at room temperature, and the solvents were removed in vacuo. The residue was purified by column 
chromatography to afford the compound 41 (0.33g, 90%) as a syrup.  1H NMR (400 MHz, CDCl3): δ 6.34 (d, 
1H, J=17.6 Hz), 6.09 (dd, 1H, J =10.8, 17.6 Hz), 5.80 (d, 1H, J=10.4 Hz), 5.25 (m, 1H), 4.53 (m, 1H), 4.11 (m, 
8H), 3.59 (m, 1H), 2.66 (m, 4H), 1.61 (m, 4H), 1.27 (m, 16H). 
 
5.1.9 Preparation of the boronic acid salt 
 
o-Bromomethylphenylboronic acid (50): o-Tolylboronic acid (1.0 g, 7.36 mmol), N-bromosuccinimide (1.57 
g, 8.84 mmol) and AIBN (0.16 g, 0.97 mmol) were dissolved in anhydrous carbon tetrachloride (100 mL) and 
the solution was refluxed for 2 h under a nitrogen atmosphere. After cooling, the precipitate was removed by 
filtration and the filtrate was washed with water (40 mL). The organic layer was separated, dried over MgSO4 
and concentrated in vacuo to dryness. The reprecipitation of the residual solid from chloroform to hexane gave 
o-bromomethylphenylboronic (50) acid (0.79 g, 50 %) as a white solid; mp 138-142 oC;1H NMR (63 MHz, 
CDCl3): δ 8.41-7.50 (m, 4H), 5.16 (s, 2H). 
 
4’,4’-N’,N’-bis(Benzyl-2-boronic acid)-bipyridinium dibromide (o-BBV) (48): Compound 50 (0.5 g, 2.32 
mmol), 4,4’-dipyridyl ( 0.18 g, 1.16 mmol) and anhydrous CH3OH ( 12 mL) were added to an oven-dried 20 
mL test tube and heated allowing the solvents to evaporate slowly until a paste appeared.  Acetone was added 
and the precipitate was removed by filtration. The precipitate was washed with acetone-H2O (24:1) twice to 
afford compound 48  (0.27 g, 63 %) as a light yellowish solid; mp >229 oC (decomposition); 1H NMR (250 
MHz, CDCl3): δ 8.98 (d, 2H, J=6.9 Hz), 8.40 (d, 2H, J=6.8 Hz), 7.72 (m, 1H), 7.52 (m, 3H), 6.00 (s, 2H). 
 
5.2 Glyconanoparticle characterization  
 
5.2.1 SEM analysis 
 
SEM measurements of the glyconanoparticles were captured on a Hitachi S800 SEM instrument in the USF 
Department of Engineering. Samples were prepared by placing a drop of diluted emulsion (1 µL of emulsion in 
30 mL of de-ionized distilled water) on the silicon wafer and evaporating the solvent by air blowing prior to 
coating with gold sputter under high vacuum. The gold-coated glyconanoparticles were then observed by SEM. 
 
5.2.2 DLS analysis 
 
DLS analyses were performed using a UPA 150 Honeywell MicroTrac DLS instrument (University of Florida 
Particle Engineering Research Center) equipped with a laser beam at 780 nm. The sample was diluted with de-
ionized distilled water (0.05 mL of emulsion in 9.95 mL of water, polymer concentration 0.1% wt) and 
sonicated for 3 minutes for the analysis. The value is expressed in weight-averaged scales as unimode at a 
scattering angle of 180 o (backscatter) at a temperature of 25 oC. 
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5.3 Microbiological test procedures 
 
 The following baceria were used for the antimicrobial evaluation of carbohydrated antibiotic drug 
monomers: Bacillus anthracis (Sterne strain), Staphylococcus aureus USF525 (ATCC 25923), Staphylococcus 
aureus  USF652-658 (obtained from Lakeland Regional Medical Center) 
 
5.3.1 MIC determinations 
 
 Media preparation: The minimum inhibitory concentrations were determined by agar plate dilution. 
The test media were prepared in 24 well plates (Coster 3524, Cambridge, MA) by adding a known 
concentration of the test drug in DMSO together with a solution of Mueller-Hinton II agar (Becton-Dickinson 
Laboratories, Cockeysville, MD) for a total volume of 1 ml in each well. Calculations of the overall 
concentration of antibiotic in the well were standardized by measuring from a 1 mg/ml stock solution of the test 
drug. At this concentration, the microliter quantity is equivalent to the micrograms in solution. The amount of 
agar solution added to the wells was determined by subtracting 1000 µL from the quantity of test drug in each 
well to give a combined volume of 1 mL. Following preparation of the well plates, the media were allowed to 
solidify at room temperature for 24 hours before inoculation. 
 
 Inoculation: From an 24 hour culture of each organism on tryptic soy agar (TSA) plates (Becton-
Dickinson Laboratories, Cockeysville, MD), the staphylococcal strains were grown overnight in 5 mL of tryptic 
soy broth (Difco Laboratories, Detroit, MI) at 37 oC. One microliter of each culture was then applied to the 
appropriate well of agar and incubated at 37 oC overnight. After 24 hr, the MIC were determined by examining 
the wells visually for growth. 
 
5.4 Fluorescence experiments 
 
 Fluorescence experiments were done using a PC1 photon counting spectrofluorometer at Larsen lab in 
the Department of Chemistry. 100 mL of dye/quencher solution was prepared in pH 7.4 aqueous phosphate 
buffer of 0.1 ionic strength. Pyranine and o-BBV concentrations were set to be 1X10-5 and 1X10-4 respectively. 
25 mg of acrylate 19 was dissolved in 5.00 mL of dye/quencher solution for sensing studies of 19. 1.00 mL of 
emulsion GNP 19 was mixed with 4.00 mL of dye/quencher solution for sensing studies of GNP 19. The 
excitation wavelength was 461.8 nm and the fluorescence emission spectrum was recorded between 470 and 
630 nm.  
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CHAPTER VI 
 
1H and 13C NMR SPECTRA 
    
 
Spectrum 6.1: 1H NMR (250 MHz, CDCl3) (1) 
 
 
 
 
 
Spectrum 6.2: 13C NMR (63 MHz, CDCl3) (1) 
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Spectrum 6.3: 1H NMR (250 MHz, CDCl3) (2) 
 
        
 
 
 
 
Spectrum 6.4: 13C NMR (63 MHz, CDCl3) (2) 
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Spectrum 6.5: 1H NMR (250 MHz, CDCl3) (3) 
 
 
 
 
 
Spectrum 6.6: 13C NMR (63 MHz, CDCl3) (3) 
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Spectrum 6.7: 1H NMR (250 MHz, CDCl3) (4) 
 
 
 
 
 
Spectrum 6.8: 13C NMR (63 MHz, CDCl3) (4) 
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Spectrum 6.9: 1H NMR (250 MHz, CDCl3) (5) 
 
 
 
 
 
 
 
Spectrum 6.10: 13C NMR (63 MHz, CDCl3) (5) 
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Spectrum 6.11: 1H NMR (250 MHz, CDCl3) (13) 
 
 
 
 
 
Spectrum 6.12: 13C NMR (63 MHz, CDCl3) (13) 
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Spectrum 6.13: 1H NMR (250 MHz, CDCl3) (14) 
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Spectrum 6.14: 1H NMR (400 MHz, D2O) (19) 
 
 
 
 
 
Spectrum 6.15: 13C NMR (63 MHz, D2O) (19) 
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Spectrum 6.16: 1H NMR (400 MHz, D2O) (20) 
 
 
 
 
 
Spectrum 6.17: 13C NMR (100 MHz, D2O) (20) 
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Spectrum 6.18: 1H NMR (400 MHz, CDCl3) (23) 
 
 
 
 
 
Spectrum 6.19: 13C NMR (63 MHz, CDCl3) (23) 
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Spectrum 6.20: 1H NMR (400 MHz, CDCl3) (27) 
 
 
 
 
Spectrum 6.21: 13C NMR (100 MHz, CDCl3) (27) 
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Spectrum 6.22: 1H NMR (400 MHz, CDCl3) (28) 
 
 
 
 
 
 
Spectrum 6.23: 13C NMR (100 MHz, CDCl3) (28) 
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Spectrum 6.24: 1H NMR (400 MHz, CDCl3) (30) 
 
 
 
 
 
 
Spectrum 6.25: 13C NMR (100 MHz, CDCl3) (30) 
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Spectrum 6.26: 1H NMR (400 MHz, CDCl3) (32) 
 
 
 
 
 
 
Spectrum 6.27: 13C NMR (100 MHz, CDCl3) (32) 
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Spectrum 6.28: 13C NMR (100 MHz, CDCl3) (34) 
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Spectrum 6.29: 1H NMR (400 MHz, CDCl3) (36) 
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Spectrum 6.30: 13C NMR (100 MHz, CDCl3) (37) 
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Spectrum 6.31: 1H NMR (400 MHz, CDCl3) (40) 
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Spectrum 6.32: 1H NMR (400 MHz, CDCl3) (41) 
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Spectrum 6.33: 1H NMR (400 MHz, CDCl3) (45) 
 
 
 
 
 
Spectrum 6.34: 13C NMR (63 MHz, CDCl3) (45) 
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Spectrum 6.35: 1H NMR (400 MHz, CDCl3) (46) 
 
 
 
 
 
 
Spectrum 6.36: 13C NMR (63 MHz, CDCl3) (46) 
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Spectrum 6.37: 1H NMR (250 MHz, D2O) (48) 
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